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Formation of tertiary lymphoid structures (TLS) occurs in tissues targeted by chronic 
inflammatory processes, such as infection and autoimmunity. In systemic lupus 
erythematosus (SLE), TLS have been observed in the kidneys of lupus-prone mice and in 
kidney biopsies of SLE patients with Lupus Nephritis (LN). Here the role of tissue-specific 
mesenchymal stem cells (MSCs) as lymphoid tissue organizer cells on the activation of CD4+ 
T cells from three groups of donors; Healthy, SLE patients and LN patients were investigated.  
Human MSCs were stimulated with the pro-inflammatory cytokines TNF-α and IL-1β 
to resemble an inflammatory condition. CD4+ T cells isolated from PBMC were co-cultured 
with stimulated and non-stimulated MSCs at 1:1 and 1:100 ratios (MSCs:CD4+ T cells) or 
seeded alone as a control. The AlamarBlue® proliferation assay was performed on CD4+ T 
cells at day zero and at day 5, 7 and 10 after co-culture. Flow cytometric analyses were 
conducted on CD4+ T cells at day zero and day 10 to analyse the Th1, Th2, Th9, Th17, Th22, 
and Th1/17 subsets before and after co-culturing with MSCs. To detect MSCs within TLS in 
kidneys of lupus-prone (NZBxNZW) F1 mice confocal imaging was used. 
After stimulation a significant increase in the expression of CCL19, VCAM1, ICAM1, 
TNF-α, and IL-1β were observed in MSCs. For all groups CD4+ T cells co-cultured with 
stimulated MSCs and non-stimulated MSCs at 1:100 ratio proliferated significantly more at 
day 10 compared to day zero and CD4+ T cells cultured. CD4+ T cells co-cultured with 
stimulated MSCs at 1:100 ratio proliferated significantly more than co-cultured with non-
stimulated MSCs at day 10 in healthy and SLE groups, but not in the LN group. No difference 
in cell proliferation at 1:1 ratio was detected. An increase in Th2 and Th17 subsets were 
observed in the healthy group at day 10 when co-cultured with stimulated MSCs at 1:100 
ratio compared to day zero and CD4+ T cells alone at day 10. MSC-like cells were detected 
within the pelvic wall of the kidneys and within the developed TLS.  
Our data suggest that tissue-specific MSCs could have pivotal roles in accelerating 
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1.1 Immune system, tolerance and autoimmunity  
The immune system is a creation of the evolution as a defence against the potential 
danger pathogenic infections generate. The immune system can roughly be divided into two 
main compartments the innate and the adaptive immune system, where the “communication” 
between these parts plays an important role in the development and control of the disease 
progression. The innate immune system involves most cell types in the body and mediates a 
general protection against infection, and can for example mediate an activation of the adaptive 
immune system through antigen presenting cells such as dendritic cells (DCs) and 
macrophages.  
The specificity of the immune system, the power of which a single pathogen are 
recognized and eliminated, lies within the adaptive immune system. The effector cells of the 
adaptive immune system are the B and T cells with their respectively B cell receptor (BCR) 
and T cell receptor (TCR) [1]. With the two processes of selective somatic genome 
modification; V(D)J recombination of both TCR and BCR in primary lymphoid tissues and 
somatic hypermutation of the BCR in peripheral lymphoid tissue, receptors with a enormous 
diversity can be produced [1].  Interesting 20-50% of the V(D)J recombined BCR and TCR 
can in the theory bind with high affinity and react to a self-antigen, but only 3-8% of the 
world population is affected by autoimmune diseases [1].  
One of the reasons why the percentages of the developing autoimmune diseases in the 
world population are so low compared to the percentages of autoreactive BCR and TCR, is 
the tolerance mechanisms involved in the developing lymphocytes and controlling of 
lymphocytes [1]. There are two main types of tolerance mechanisms acting on the developing 
lymphocyte: central and peripheral tolerance [2], illustrated in Figure 1.1 and further 
explained in section 1.4 Lymphoid organs.  
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Figure 1.1: Tolerance mechanisms for controlling and removing of autoreactive lymphocytes.  
In central tolerance an autoreactive lymphocyte can be removed during their development in either the thymus or in the bone 
marrow. There are three main mechanisms for central tolerance; BCR change in autoreactive B cells, development of Treg 
cells or that the autoreactive lymphocyte dies via apoptosis. In peripheral tolerance the autoreactive T or B cell can either be 
functional inactive in a process known as anergy, die via apoptosis or of autoreactive T cells be controlled by Treg cells. 
Modified from ref [2] 
Autoimmunity arise when an organisms immune system start to produce an immune 
reaction against its own cells, tissues and/or organs [3]. The knowledge about the existence of 
autoimmune diseases has been known for over 100 years with more than 80 human diseases 
being investigated, but the underlying initiation mechanisms for why autoimmunity exists are 
still a mystery among scientists [3]. It is clear that there are three main phases of an 
autoimmune disease; initiation, propagation and resolution (Figure 1.2), which all can be 
linked to a deficiency in the immune regulatory mechanisms [4]. 
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Figure 1.2: Common disease progression in autoimmune diseases. Normally when the patients are in the resolution phase, 
a relapse occurs and acute inflammation with tissue damage are observed [4]. 
 
1.2 Systemic Lupus Erythematous  
Systemic Lupus Erythematous (SLE) is an autoimmune rheumatic disorder that can 
affect multiple organs systems, which is a result after a loss of immunological tolerance and 
immune response against self-antigens [5, 6]. The diagnosis of SLE follows the 1997 updated 
version of the 1982 revised criteria by the American College of the rheumatology (ACR) [7, 
8] where it is required that the patient have the presence of four out of eleven criteria before 
the diagnosis SLE is set [6, 7]. In addition to the ACR classifications the severity of SLE is 
assessed by the SLE disease activity index (SLEDAI), which is a scoring system that includes 
24 clinical and laboratory variables that are weighted differently according to how life 
threatening the manifestation is [9, 10]. From these criteria it is obvious that this disease may 
affect some if not most of the vital organs and tissues of the body, implying it is crucial that 
the diagnostic tools and therapeutic agents are further developed to improve the life and 
health quality of the patient. 
It is common knowledge that one of the major risk factor for SLE is gender, observed 
by that at least 9 out of 10 patients are women [6, 11, 12].  The incidence of SLE is varying 
worldwide depending on the geographic and ethnicity. Studies from United Kingdom (UK) 
and North America observed that Afro-Americans and Asians had a higher risk to develop 
SLE than other ethnical groups [13]. In Scandinavia the total annual incidence rate (AIR) is 
lower, between 2.35-3.5/100 000 [5, 10, 13, 14], compared to countries with a much wider 
ethnicity spectrum such at United Kingdom (total ACI; 4.7-4.9/100 000)[15, 16] and USA 

















prevalence of SLE in Norway were calculated to be in total 51.8/100 000, where the 
prevalence for women were 91.0 and for men 10.7 [13].  At approximately the same time 
Lerang published her data, Hermansen and colleagues calculated the prevalence of SLE in 
Denmark. Interesting the prevalence from Denmark were lower than the prevalence in 
Norway with a total prevalence of 45.2/100 000, 79.6/100 000 for women and 10.1/100 000 
for men [5]. 
 
1.2.1 Pathology SLE 
The one and exact factor for the disease development in SLE is sadly still unknown, 
making it difficult to predict, diagnose and treat. In Figure 1.3 some of the more common 
factors that might stimulate disease development are illustrated, but it is wise to be aware that 
development of the disease often are caused by a mix of several factors [19, 20].  Figure 1.3 
also illustrates some of the most common immunological effects and which organ that are 
associated with SLE. One of the most central immunological disturbance in SLE is the 
production of autoantibodies, which is an important contributor in the pathogenicity and 
diagnostic of the disease. Antinuclear antibodies (ANAs), which are found in 90 to 95% of 
SLE patients [21], are antibodies that can recognize and bind to components in the cell 
nucleus, such as DNA, RNA, nuclear protein, and the protein-nucleic acid complexes 
nucleosome and spliceosome [21, 22]. In SLE there are several factors that could contribute to 
the development of autoantibodies, but the deficiency of removal of apoptotic cell debris 
might be one of the leading mechanisms [23]. 
 
Figure 1.3: Overview of some of the pathogenically hallmarks of SLE.  This illustration was inspired by “Figure 1” in the 
review article “Mechanisms of disease - Systemic Lupus Erythematous” published in 2011 by G.C Tsokos.  
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1.2.2 Lupus nephritis 
Lupus nephritis (LN) is the kidney manifestation of the SLE autoimmune disease and is 
one of the more severe manifestations of SLE [21]. 25% to 60% of the patients with SLE are 
affected by this renal manifestation and this occurs often during the first year of disease 
course [10]. Classification of LN follows the classification system provided by the 
International Society of Nephrology and the Renal Pathology Society from 2003 (ISN/RPS 
2003) [24]. This criteria system is based on the glomerular changes in LN patients, from when 
immune complexes deposits (ICs) in the glomerular to when sever scaring occurs and the 
function of the glomeruli are lost and proteinuria is observed.  
The pathology of LN (Figure 1.4) is characterized by deposition of immune 
complexes (IC) in the glomeruli, which will lead to an inflammatory cascade with activation 
of Fc receptors (FcR) and Toll-like receptors (TLRs) on the cells in the glomeruli and the 
tubulointerstitium [20, 21, 25-27]. Activation of these receptors will stimulate the production 
of proinflammatory cytokines such as IL-1, IL6, TNFα and monocyte chemoattractant protein 
1 (MCP-1), which again will contribute to the recruitment of immune cells [26, 28]. In 
addition to the production of proinflammatory cytokines, the cells in the kidney will also start 
the production of extracellular matrix (ECM) compounds [29]. These ECM compounds 
promote the scaring formation in for example the glomeruli and causes glomerulosclerosis, 
leading to organ failure and proteinuria [29].  
Deposition of ICs in the glomeruli might also stimulate mesangial cells to proliferate 
and expand the mesangial matrix, leading to a reduced flow of filtrating in the glomerular 
capillaries and thereby eventually seal the capillary lumen [30]. The fenestrated endothelial 
cells in the glomeruli will also be activated and start to express adhesion molecules such as 
VCAM-1, ICAM-1 and E-selectin, when the ICs are deposited in the glomeruli [25, 31, 32]. 
These adhesions molecules are important for the recruitment and infiltration of immune cells 
to the subendothelium and mesangium [25, 32]. The deposition of ICs in glomeruli and with 
the infiltration of immune cells and expanding mesangium, add a huge stress on the 
specialized glomerular epithelial cells; the podocytes. One of their main responses is the loss 
of their characteristic pattern of foot processes in a process called effacement in podocyte foot 
processes [33]. In a study by Wang et al. from 2014, a positive correlation between the widths 
of the foot processes and the level of proteinuria was observed [34]. These findings might be 
explained with that the foot processes are important for the filtration processes in the 
glomeruli, and when they are damaged the filtration will be affected and interrupted in a way 
leading to proteinuria [33].  
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Infiltrating leukocytes are also associated with formation of tertiary lymphoid 
structures (TLS) with active germinal centres (GCs), which will promote B cell differentiation 
into antibody secreting plasma cells and stimulate a local production of autoantibodies [26]. 
Chang and colleagues published in 2011 the first article where they describe how infiltrating 
immune cells are capable organize into B-T cell aggregates and GCs in lupus patients with 
nephritis [35]. From this study, they found that there was a correlation between the B-T cell 
aggregate and GCs formation and the IC deposition in the tubular basement membrane [35].  
 
 
Figure 1.4: Some of the possible outcome when circulating immune complexes and ANAs are deposited in the kidney. 
When ICs are deposited in the glomeruli or in the tubulointerstitium they will activate the cells in the tissue to produce 
proinflammatory cytokines and chemokines, which will recruit immune cells to the site of inflammation. The kidney cells 
will also have an increased production of ECM components leading to fibrosis. TLSs have been observed in kidneys of LN 
patients and in murine models of LN. The end outcome of the damaged kidney is eventually kidney failure with proteinuria. 
Based on ref [20, 26, 29, 34, 35] 
 
	 	












































1.3 Immune cells 
The soldiers of the immune system are the immune cells, which are composing both the 
innate and adaptive immune system (Figure 1.5). The innate immune system could be viewed 
as the first line defence and the cells in this part of the immune system are the first one to 
react to a pathogen exposure [36]. The phagocytic cells, such as neutrophils and 
macrophages; cytotoxic natural killer cells and granulocytes will carry out the effector 
functions of the innate immune responses [36, 37]. The adaptive immune responses will 
immediate an antigen-specific defence with the development of the (long lived) antigen-
specific lymphocytes; B and T cells [36, 37]. Antigen-presenting cells, which include cells 
from the innate immune system such as macrophages and DCs, are important in the activation 
and priming of the antigen-specificity of the adaptive immune system. In this study the T cells 
from the adaptive immune system are in focus and will therefore be discussed further.  
 
 
Figure 1.5: Immune cells of the innate and adaptive immune system. The innate immune system consist of the dendritic 
cells, the granulocytes (basophils, eosinophils, neutrophils), macrophages, NK cells and mast cells, while the adaptive 
immune system consists of the antibody producing B cell, the CD4+ and CD8+ T eclls. γδ T cells and NK-T cells cytotoxic 
lymphocytes that straddle the interface of innate and adaptive immunity. B; B cells, BG; basophil granulocyte, DC; Dendritic 
cells, EG; eosinophil granulocyte, MC; Mast cell, Mφ; Macrophage, NK; natural killer cells, NKT; natural killer T cells, T; T 
cells, CD4+Th; CD4+ T helper cells, CD8+ CTL; CD8+ cytotoxic T cells, γδ-T; gamma delta T cells.  Figure modified from 





1.3.1 T cells and their main linages   
T cells are lymphocytes that play an important role in cell-mediated immunity, and are 
characterized with their expression of their T cell receptor (TCR). These cells develop in the 
bone marrow and are primary matured in the thymus as discussed in the Section 1.4.1. The T 
cells are broadly divided into the two main linages, αβ and γδ, based on how their TCR are 
composed of [38].  The first combination of the TCR consist have α and β chains, and most 
of the T cells belong to this class. TCR of both the sublinage of CD4+ T helper cells (Th 
cells) and the cytotoxic CD8+ T cells (CTL) consist of α and β chains. These cells will 
recognize antigens presented on the MHC molecule to either assist other cells in 
immunological effector functions (Th Cells), or to kill infected cells and cancer cells (CTL). 
In the αβ linage of T cells consists also of the Natural killer T (NKT) cells, which have both 
phenotypic and functional characteristics found in both conventional NK cells and αβ-T cells 
[39]. The NKT cells have the ability to recognize lipid antigens presented by the CD1d-
molecule cell types present in the intestine and liver, and could thereby contribute to the 
immune responses in the digestive system for both promoting health and disease [39].  
The second main linage of T cells, the γδ T cells, show several innate cell-like features 
that permit early activation and recognition of conserved non-peptide ligands presented by 
stressed cells [40]. Interesting these γδ T cells are mainly located in mucosal tissues and on 
epithelial surfaces, such as the gut mucosa, skin, lungs and uterus, where they migrate early in 
their development [40]. The main functions of the γδ T cells varies from a protective 
immunity against extracellular and intracellular pathogens, tumour surveillance, modulation 
of both innate and adaptive immune reactions to tissue healing and regulation of the function 
of a physiological organ [40].  
 
1.3.2 The family of CD4+ Th cells 
The CD4+Th cells are further divided in to subsets based on the differentiation of 
naïve CD4+ T cells, which depends on the antigen, the strength of the TCR signal and the 
cytokines in the environment [41] (Figure 1.6). In 1986 Mosman and Coffman distinguished 
Th1 and Th2 subsets form each other based on the cytokine profile of these two subsets [42]. 
The main functions of Th1 cells are involved in cell mediated inflammation, defence against 
intracellular pathogens and in delayed-type hypersensitivity reactions [43]. The Th1 cells are 
known for their production of the characteristic cytokines: IL-2 and IFNγ, but they can also 
produce other cytokines such as TNFα and LTα [43]. The T cells of the Th2 subset are 
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involved in humoral-mediated immunity and their main function are to defend the host 
against extracellular pathogens, but unfortunately the Th2 subset are also associated with 
allergy, eczema and asthma [43, 44]. The characteristic cytokine profile of the Th2 subset 
consists of IL-4, IL-5 and IL-13, as well as IL-9 ad IL-10. IL-4 is a cytokine with several 
functions for other lymphocytes and for cells from the innate immune system. The IL-4 
cytokine promote activation in macrophages and monocytes, stimulate development and 
maturation of dendritic cells, and for plasma cell differentiation and antibody isotype 
switching to IgG1 and IgE [43].  
 After the discovery of Th1 and Th2 subsets of CD4+T cells, several subsets of CD4+ 
T cells have been classified such as Th9, Th17 and Th22 cells, T regulatory cells (Treg) and 
follicular helper T cells (Tfh) [43]. The Th17 subset is characterized by its expression of IL-
17, primarily IL-17A and IL-17F, in addition to their expression of TNFα, IL-6, IL-22, IL-21 
and IL-26 [43, 45]. The main function of the Th17 subset involves the host defence against 
extracellular bacteria, fungi and viruses [43, 45], where these cells stimulate production of 
antimicrobial peptides, increase the barrier function of epithelial cells and lead to recruitment 
of neutrophils and monocytes to the site of inflammation [46]. The Th9 subset of the CD4+ T 
cell repertoire are one of the main producers of IL-9, which will stimulate inflammation by 
promoting the growth of leukocytes such as mast cells and the secretion of chemokines that 
will stimulate the recruitment of more immune cells to the site [47]. In addition to their 
production of IL-9, the Th9 cells can also produce IL-10, which is an anti-inflammatory 
cytokine and indicating that Th9 cells might perform immune regulatory mechanisms [43]. 
The newest member to the Th subset is the Th22 cell, which has several similarities to the 
Th17 cell with the production of IL-22 [43]. The IL-22 is a member of the IL-10 family, 
indicating that the role of Th22 cells in host defence acts on non-immune cells and promote 
enhancement of innate immunity and tissue regeneration [43, 48].  
The linage of Treg cells are a subset of specialized T cells that execute suppressive 
functions of other effector T cells and could be seen as a “police” or a “break” of the immune 
system. Their main task is to control and supress overactive immune cells [43]. Some 
examples where they have an important role are: their suppression of allergy; in the 
establishing of tolerance to organ grafts and to prevent graft-versus-host disease; and to 
promote feto-maternal tolerance in pregnant women [49]. αβTCR linage of Treg cells are 
characterized by their transcription factor FoxP3 and can be developed in the thymus 
(nTregs), as a result of central tolerance, or they could be induced via post-thymic maturation 
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(iTreg) that often are characterized as CD4+CD25+FoxP3+ [43]. The Tregs uses multiple 
methods to perform their effector functions: one through modulation of APCs and thereby 
indirectly supress T effector function, or by directly suppress T and B cells [50]. Treg cells 
can secrete of anti-inflammatory cytokines (IL-10 and TGFβ), which will inhibit the 
proinflammatory effector functions of lymphocytes and APCs [50]. Treg cells are also 
capable with expression of inhibitory receptors (CTLA-4) [43], which can down regulate the 
expression of MHC-II molecule and the costimulatory molecules CD80/CD86 and CD28 on 
the APC [43, 49]. The Treg can induce apoptosis in T cells or APCs through cell-to-cell 
contact by a granzyme or perforin mechanism, or via the stimulation of tryptophan catabolism 
in APCs through indoleamine 2,3-dioxygenas (IDO) that produce the T cell toxic compound 
kynurenines [49]. 
The follicular helper T cells (Tfh) are a specialized subset of T cells whose main task 
is to provide B cell help in the GCs together with follicular dendritic cells (FDCs) [51]. 
Through their expression of surface molecules and chemokines such as; CD40L, IL-21, IL-4, 
PD-1, and BAFF, they will regulate the B cell survival and proliferation, participate in the 
initiation of somatic hypermutation and differentiation of B cells into plasma B cells and 
memory B cells [51]. The Tfh can also induce apoptosis via Fas-FasL interactions in B cells 
that fail to present cognate antigen [51].  
 
Figure 1.6: The CD4+ Th subsets; their inducing cytokines, their expression of transcription factor, and their main 
production of chemokines. The chemokines and transcription factors included are only some of the factors that will 
determine the fate of the naïve CD4+ T cell. Information from Table 1 by Tangye et.al (2013) [48] 
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1.3.3 CD4+ T helper cells and their role in lupus  
It is observed that T cells from patients have abnormal phenotypes and functions [52], 
which can lead to exaggeration of TCR response to a stimuli and the T cells get activated [19, 
53]. The CD4+ T helper cells are important in the production of autoantibodies and tissue 
inflammation, and they have a strong connection to the pathogenicity of SLE and LN [54] 
(Figure 1.7). All the cytokines produced by Th1 and Th2 are important for the pathogenicity 
of SLE and lupus prone mice that are IFNγ-/- and IL-4 -/- have reduced lymphadenopathy and 
end-organ disease compared to the cytokine sufficient control group [55]. In murine models 
of SLE, deficiency in the IFNγ and IL-4 have shown to be important for the pathology of the 
disease [43, 56].  
Today it is clear that other subsets of T cells, both within the Th family and in other 
subset of T cells, are of high importance in the contribution to the immune disturbance in SLE 
[6, 57]. An increase in the IL-17-levels in the blood and tissues (kidney, skin) from lupus 
patients have been observed [54], indicating that the Th17 cells are involved in the 
pathogenicity of lupus. From murine models IL-17 have shown to promote spontaneous 
formation of ectopic GCs, stimulate loss of B-cell tolerance and maturation of B cells into 
plasma cells, in addition to induce autoantibody production in these B cells [43, 54, 56]. IL -
17 have also been associated with infiltration of NK cells and neutrophils, and an increased 
IFNγ production by NK cells, CTLs and Th1 cells has been detected in patients with nephritis 
[56].  Circulating follicular helper-like CD4+ T (cTfh-like) cells have been observed to be 
associated whit the disease activity in SLE patients were, which can indicate that the 
regulation of the maturation of naïve B cell might be disturbed and promote the development 
of ectopic GCs [58, 59]. The development of the different Th effector-subsets and the Tfh are 
under control of Treg cells [49]. If the balance between the effector and regulatory cells is 
disrupted, the chances of developing autoimmune diseases are increased [49]. Impaired 
functions and reduced numbers of Treg cells in patients with lupus have been reported, and 
are linked to the disease progression in SLE (reviewed in [60]). In 2005, Hatashi and 
colleagues found depletion of Treg cells in murine models resulted in increased titers of 
ANAs and an early development of glomerulonephritis compared to the control [61]. These 




Figure 1.7: Dysregulation of T cell function and subset population in SLE pathogenesis.  Reduced effector functions of 
the Treg and the CD8+ CTL stimulate an increase in pro-inflammatory Th and Tfh subsets, which infiltrate tissues, enhance 
the inflammation processes, and stimulate autoantibody production. DN-T cells are also observed to contribute to the disease 
pathology through their production of IL-17. Green arrows indicating upregulated pathway and red arrows indicating down 
regulated pathway. Modified from figure 1 from Suárez-Fueyo et.al (2016) [54] 
  
1.4 Lymphoid organs 
Even though good defences against infections are scattered in tissues throughout the 
body, the optimized structures to create pathogen specific lymphocytes include the lymphoid 
organs. These organs are important for the production and activation of “combat approved” 
lymphocytes, which during normal conditions are not self-reactive. The lymphoid organs can 
be divided into three main categories; primary, secondary and tertiary lymphoid organs or 
tissues, and their main function and development will be discussed in this section.  
 
1.4.1 Primary lymphoid organs  
Primary lymphoid organs are defined as organs, or compartments within organs, 
where hematopoietic progenitor cells differentiate into an abundance of immune cells capable 
of performing effector functions [62]. There are three main types of primary lymphoid organs: 
the bone marrow, the thymus and the fetal liver, which will follow a programmed 
development during embryogenesis [62]. In addition to produce immune cells with effector 
function, the primary lymphoid organs also hold the site of central tolerance mechanisms 
(Figure 1.1).  
In the adults the bone marrow harbour the source of self-renewing stem cells such as 
hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and endothelial progenitor 
cells, in addition to various progenitor cells that have started their pathway in differentiation 
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and specialization into specific cell types [62, 63]. One of the main functions of the bone 
marrow is to produce erythrocytes, platelets and leukocytes such as neutrophils, monocytes 
and mast cells, just to mention some of the common leukocytes. The bone marrow is also the 
site of B cell maturation, where IgM producing B cells are developed before they are 
distributed into the blood. The central tolerance of B cell maturation occurs in the bone 
marrow, where a combination of positive and negative signals from the BCR and co-receptors 
together with signals from survival factors (i.e. BAFF) will determine the fate of the B cell [2, 
64]. The three outcomes of these signals are the survival and activation of the developing B 
cell, the clonal deletion by apoptosis or the B cell will reach an inactivated anergic phase. 
Self-reactive B cells can undergo receptor editing, where an additional light chain VJ 
recombination and new Ig light chain production occurs, in the hope of changing the BCR 
specificity not self-reactive. If the outcome of the receptor editing still creates a self-reactive 
B cell, the B cell dies via apoptosis [64]. 
The thymus is the main location where lymphocyte progenitors cell undergo a 
multistep maturation, differentiation, expansion and selection program to become either a 
naïve CD4+ or CD8+ T cell [62], which can be activated in secondary lymphoid organs and 
mediate cellular immunity. In this maturation program of T cells, there are some essential 
checkpoints that the developing T cell has to pass before it is released into the circulation as 
mature naïve CD4+ or CD8+ T cell.  T progenitor cells (thymocytes) entry the thymus in the 
corticomedullary junction and start their journey through out the thymus [65]. At this stage 
the thymocyte lack the expression of the TCR, CD4 and CD8, and are termed double-negative 
(DN) thymocytes. In the cortex of the thymus these DN thymocytes goes through four stages 
of differentiation and simultaneously starts to express their pre-TCR molecule [66]. When the 
thymocyte manages to successfully express the pre-TCR, the thymocyte will proliferate and 
become double positive (DP) thymocytes with their expression of CD4 and CD8 [62]. Then 
the TCR on the DP thymocytes will interact with peptide-MHC complexes that are expressed 
by cortex stromal cells, such as cortical thymic epithelial cells (cTEC) and DCs in the cortex. 
Low-avidity interactions will induce the DP thymocytes to receive signals for survival and 
differentiation into single positive (SP) thymocytes [65].  The next event in the developing 
thymocyte is the central tolerance, which occurs in the medulla of the thymus. Here the 
autoimmune regulator (AIRE) expressing medullary thymic epithelial cells (mTEC) will 
interact with the SP thymocytes through peptide-MHC complexes, and recognize thymocytes 
which binds to strongly to the complex [65]. These self-reactive thymocytes will either fate 
death by apoptosis or be stimulated to become FoxP3+ nTreg cells [65]. Sphignosine-1-
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phosphate receptor 1(S1P1) expressing mature T cell, which have overcome all the 
developing checkpoints in the thymus, will be attracted to the circulation where they can be 
activated and become effector T cells [65].  
 
1.4.2 Secondary lymphoid tissues 
Lymph nodes, spleen, and mucosa associated lymphoid tissues (MALTs), such as 
payer’s patches (PPs) and tonsils, are common known as secondary lymphoid organs (SLOs) 
located statically within the lymph and blood [62, 67, 68]. The organization of the immune 
cells share several similarities   
 The lymph node is a highly organized organ that is surrounded by a capsule, and the 
three main compartments are the cortex, the paracortex and the medulla [62, 69]. The cortex 
contains B cells, macrophages and follicular dendritic cells (FDCs) arranged into primary B 
cell follicles, where the chemokine CXCL13 produced by the FDCs plays the dominant role 
in the position of the B cells via the interaction with CXCR5 [62]. In the primary follicles B 
cells immunity are mediated by FDCs [70]. These FDCs can present antigens in form of 
immune complexes that are bound via Fc and complement receptor, and thereby stimulate B 
cells through the BCR receptor and promoting germinal centre formation [70]. The T cell 
zone located in the paracortex are mainly composted of T cells, DCs and fibroblastic reticular 
cells (FRCs), where the chemokines CCL19, CCL21 and CXCL12 are important for the 
organization and recruitments of T cells and DCs [69]. It is in the T cell zone naïve T cells are 
activated by antigen-presenting cells APCs, which in most cases are mature DCs. In between 
the cortex and paracortex are the location of the secondary B cell follicles and germinal 
centres (GCs), where Tfh cells are involved in somatic hypermutation and isotope switch of 
the B cells Ig-molecule [71]. The most inner layer of the lymph node, the medulla, consists of 
the medullary cords that are separated by the lymph filled spaced of the medullary sinuses 
[69]. In the lymphatic sinuses, the filtration of lymph from afferent lymph vessels occurs, 
before the compounds from the lymph flows to the B cell area in the cortex or via the 
subscapular sinuses and out of the lymph node via the efferent lymphatic vessel [71]. The 
afferent and the efferent lymphatic vessels lined with lymphatic endothelial cells, together 
with the high endothelial venules (HEVs), complete the vasculation of the lymph node [71].   
B and T cells will, together with blood antigens, enter the lymph node via HEVs in a 
process known as the leukocyte adhesion cascade [62]. The HEVs in the lymph node express 
a special selectin ligand called pheripheral LN adressin (PNAd) on their luminal surface, 
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which will interact with the L-selectin (CD62L) on B and T cells and initiate the rolling 
cascade. The chemokines located at the HEVs; CCL19, CCL21, CXCL12 and CXCL13, are 
important for guiding and select the B and T cell via their chemokine receptors (CCR7, 
CXCR4 and CXCR5) into the lymph node. These chemokines will activate the chemokine-
triggered adhesion to the HEVs, which involves activation of the α1β2 integrin to 
ICAM1/ICAM2 on the HEVs. [62] 
 
Immunological properties  
The main functions of the SLOs are to filter the blood and lymph to trap and 
concentrate foreign antigens in addition to attract antigen-presenting cells (APCs), which have 
brought in antigens from surrounding tissues, to initiate an adaptive immune response with 
activation of naïve lymphocytes [62, 63, 67, 72]. Second important functions of the SLOs are 
their capacity to execute mechanisms for peripheral tolerance. There are several ways that the 
tolerance mechanisms are archived, and are involved with several cell types inside the SLOs. 
The essential parts in the decision of the fate of the naïve lymphocytes lies in the presence or 
absence of antigen, co-stimulation, cell interaction and/or chemokines/cytokine [69].  
In the classical activation of naïve T cells, the naïve lymphocyte needs two types of 
signal to be fully activated. The first signal is depended of the TCR:MHC interaction between 
the T cell and the APCs, while the second signal is provided to the T cell by the APC and it is 
composed of costimulatory molecules such as CD80/CD86 and chemokines [73]. Usually the 
APC that are involved in this process are mature DCs, which have migrated from surrounding 
tissues after they have been activated by a “danger signal” via their pattern recognition 
receptors  (PRRs) and captured antigens. In for example the lymph node, there are several 
immature DCs that have not been activated but can present antigens on their MHC-II 
molecules [74]. If the MHC-II molecule on this immature DC interacts with the TCR on a 
naïve CD4+ T cell, the T cell either dies or become anergic since the immature DCs can’t 
provide with the important second signal with the expression of costimulatory molecules [74, 
75].   
Initially stromal cells were thought to be mainly involved in supporting of the 
structure of SLO [69, 75]. However, later research has found that they can also serve an 
important immunological function in the regulation of the adaptive immune system [69, 75]. 
These stromal cells, especially the fibroblastic reticular cells (FRCs), can express peripheral 
tissue-restricted antigen (PTAs), such as proteins associated with pancreas, eye, intestine, 
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thyroid, skin, CNS and liver, in a similar fashion as the mTECs does in the thymus [76]. The 
PTA expression has shown to induce anergy and subsequent elimination of CD8+ T cells, and 
might be a method to increase the odds for eliminating rare, self-reactive T cells [76].  
 
Development of secondary lymphoid organs 
The development of the SLOs is a pre-programmed process and occur either during 
the embryogenesis or early in the post-natal period [68]. The SLO development requires the 
interaction between the mesenchymal stromal cell expressing the lymphotoxin-β receptor 
(LTβR) and the hematopoietic lymphoid tissue inducer (LTi) cell, which express the 
lymphotoxin-α1β2 (LTα1β2) complex [70, 72]. LTα1β2 is a heterotrimeric complex 
belonging to the TNF superfamily, it is composed of the membrane-bound LTβ2 and the 
soluble LTα1 and by binding to its receptor LTβR will initiate a signalling cascade necessary 
for the developing lymphoid organ and the interaction is necessary for the maintenance of the 
organized structure [77].  
 The LTi cells are derived from the family of type 3 innate lymphoid cells (ILC3) and 
are characterized by their expression of being ID2+RORγt+CD4+ [78, 79]. The development 
of the LTi cells from the ILC3 is strictly depended on their expression of the transcription 
factors RORγt and the ID2 and the TNF family ligand-receptor pair RANKL-
RANK/TNFRSF11A [79], where the RORγt expression are controlled by maternal retinoic 
acid [78].  Figure 1.8 illustrates the main events that occur during SLO development. Before 
the interaction between the LTo cells and the LTi cells occurs, the LTi cells need to be 
clustered in a LTα1β2/LTβR independent manner [72, 80].  
The chemokine CXCL13 produced by the mesenchymal stromal cells are important 
for the initial clustering of LTi cells by binding to the CXCR5 on these cells [81], and 
activation of the CXCR5 results in increased levels of LTαβ on their cell surface [79]. In 
mice with deficient CXCL13 and CXCR5 signalling have an insufficient development of 
peripheral lymph nodes [81] and the white pulp in spleen [82]. The production of the 
CXCL13 chemokine is under the control of retinoic acid from neurons, observed by retinoic 
acid producing neurons are located near to CXCL13 expressing stromal cells near the 
branching site of blood vessels [81]. Retinoic acid will control the gene expression of 
CXCL13 by binding to DNA-binding RA receptors (i.e. RARβ), which then will bind to the 
retinoic-acid-responsive elements (RARE) in the CXCL13 gene and induce the CXCL13 
production [81].  
 25 
The increased expression of LTαβ on the LTi cells promote the LTα1β2/LTβR 
interaction between the LTi and the mesenchymal stromal cells, and results in maturation of 
the mesenchymal stromal cell into lymphoid tissue organizer cell (LTo). The LTo are 
characterized with their expression of the adhesion molecules (VCAM-1, ICAM-1 and 
MADCAM-1) and their increased production of the homeostatic chemokines (CXCL13, 
CCL19 and CCL21) [72, 79, 80]. The LTo cells will also produce interleukin-7 (IL7), which 
together with the homeostatic chemokine upregulation lead to a positive feedback loop that 
will result in an increased recruitment of LTi cells [80]. The LTo cell will also contribute to 
the incorporation of lymphatic endothelial cells (LECs) by expressing VEGF-C [62]. LTo 
cells secreting potent vascular growth factors will stimulate LTβR expression on endothelial 
cells, which are important for the differentiation into HEVs [83]. In addition the LTβR 
signalling is necessary for maintenance and homeostasis of this HEV network in the 
developing SLO [83]. The LTo will later in the SLO development differentiate into the non-
haematopoietic stromal cell types such as FDCs and FRCs [80]. In development of PPs in the 
small intestine, a second distinct population of CD4-CD45+ ILRα- CD11c+ lymphoid tissue 
induction (LTin) cells are involved in the stromal activation in the developing organ [80]. 
 
Figure 1.8: The first events in the developing SLO.1. Retinoic acid from nerve cell will stimulate mesenchymal stromal 
cell to produce CXCL13, which will interact on the CXCR5 receptor on a LTi cell (2.).  The LTi cell will respond with 
production of LTαβ (3.), which will interact with the LTβR on the stromal cell and stimulate differentiation into LTo cell 
(4.). The LTo cell will produce a positive feedback and recruit more LTi cells to the site by producing CCL19 and CCL21 
(5.). The LTo cell will also contribute the formation of HEVs and incorporation of lymphatic endothelial cells (LECs) to the 
structure (6.). In the later stages of the developing SLO, the LTo cell will further differentiate into FRCs and FDCs (7.) 
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1.4.3 Tertiary lymphoid structures  
Tertiary lymphoid structures (TLS) are ectopic accumulation of lymphoid, myeloid 
and stromal cells, which occur after birth and are often observed as a response to an 
environmental stimuli and/or the transition from an acute to a chronic inflammation [62, 79]. 
TLSs are observed in a large variety of diseases ranging from several autoimmune diseases 
[84], cancer [85], infections [86], to transplant graft rejections [86]. How the TLS is organized 
varies between the site of inflammation, organ affected and individual variance between each 
patient. The degree of organization ranges from oligocellular accumulation of B and T cells to 
more sophisticated structures similar to SLO with distinct B and T cell area, active GCs, 
PNAd+ or MAdCAM-1+ HEVs, FRCs and FDCs [62]. The TLS formation is a reversible 
process, observed with that they can decrease in size after the removal of the initiating 
stimulus or after therapeutic intervention, and thus making TLSs to be a quite plastic 
lymphoid organ [67].  
The development of TLS, or the neogenesis of the TLS, shows several similarities to 
the SLO development regarding the chemokine/cytokine and adhesion molecule expression 
patterns [79]. One of the most dominant similarities is the expression of homeostatic 
chemokines (CXCL13, CCL19, CCL21 and CXCL12) and signalling through LTα1β2/LTβR 
leading to the positive feedback loop that guide the recruitment and organization of 
lymphocytes [87]. The more striking differences between the SLO and TLS development are 
that the TLS development does not require fetal derived CD4+CD3-RORγ+Id2+ LTi cells and 
inflammatory events are triggers for the TLS development, while the SLO development is 
depended of fetal derived LTi and is pre-programmed during embryogenesis [87]. The 
questions then arise regarding which cell type can function as an LTi cell candidate in the 
developing TLS. Infiltrated immune cells, such as DCs, macrophages, Th17 cells and γδ T 
cells could function as an LTi-like cell and express LTα1β2 [77, 86]. Recent studies have 
shown that the cytokine IL-17, which are produced by Th17 and γδ T cells, are important in 
the initiation of TLS structures [77]. The cells that can act as an LTo cell candidate in the 
developing TLS are the stromal cells (from a mesenchymal progenitor cell) in the inflamed 
tissue; the fibroblasts, myofibroblasts and the perivascular cells, which under stimulation by 
proinflammatory cytokines can express LTβR and produce compounds for recruitments of 
LTi-like cells leading to the formation of TLS [88]  
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Tertiary lymphoid and diseases  
What outcomes, both beneficial and detrimental, are associated with TLS formation in 
a host? To answer this question the case studied has to be defined, since there are both pros 
and cons with this ectopic lymphoid tissue development. In viral infections, such as in acute 
influenza virus infection, bronchial-associated lymphoid tissue (iBALT) formation in the 
lower respiratory tract is observed and induces a host protective role against the infection 
[89].  
On the opposite site of the scale, the development of TLS might be the cause of the 
induction or exacerbating of an autoimmune reactions and thereby is associated the 
detrimental effects [80]. Activation of autoreactive B cells in TLS is not so strictly regulated 
compared to the activation of B cells in the SLOs, increasing the risk of differentiation and 
expansion of these autoreactive B cells and promote a local production of autoantibodies in 
the inflamed tissue [90].  TLSs have been associated with several autoimmune diseases and 
where these structures develop are related to where the immune system usually attack in the 
disease [89]. For example TLSs have been observed in the joints and lung of patients 
suffering of rheumatoid arthritis [91], in the salivary glands in Sjögren’s syndrome [92], in the 
pancreas in diabetes [93], and in the kidney of SLE patients [35]. TLS formation in patients 
might also affect how they are responding to the therapy, making it challenging to treat this 




1.5 Stem cells  
Stem cells are characterized with their differentiation potential to become multiple 
mature cell types and their ability to self-renewal, which are important to replenish the stem 
cell pool [94, 95]. The ability to differentiate into various cell types is described with the 
potency of the cell. The more cell types a stem cell can be the ancestor of, the higher is its 
potency, which can range from a totipotent (ie. Zygote) to unipotent (ie. spermatogonial stem 
cells) [94]. The stem cells can broadly be divided into two main categories; the embryo stem 
cells and the adult somatic stem cells, also known as the nonembryonic stem cells [96]. The 
embryo stem cells are isolated from the inner mass of a blastocyst and are derived from the 
totipotent zygote [94, 96]. The embryotic stem cells, categorized as pluripotent stem cells, 
have the ability to become the ancestor of all the cells in a developing fetus and some of the 
extra embryonic cells such as cells in the placenta [94]. The adult somatic stem cells can be 
found in adults and children, but also in the infants, placenta and the umbilical cord blood 
[96]. These adult stem cells are known to be multipotent, meaning that they have the capacity 
to generate the mature cell type of their tissue origin, but will not differentiate into unrelated 
linages under normal physiological circumstances [94]. The bone marrow harbours two types 
of adult somatic stem cells; the hematopoietic stem cell (HSCs) and the mesenchymal stem 
cell (MSCs) [96]. In this study MSCs are in focus, and their functions and role in medicine 
are further discussed.  
 
1.5.1 Mesenchymal stem cells  
Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, are 
nonhematopoietic stromal cells that have the potential to differentiate into tissues of 
mesenchymal origin such as bone, cartilage, adipose, connective tissue, smooth muscle and 
hematopoietic supporting stroma [97, 98]. Isolation of MSCs have been successfully 
performed from various tissues such as bone marrow, adipose tissue, nervous tissue, placenta, 
menstrual blood and dental pulps [99, 100]. A challenge in the field of the study of MSCs 
have been the lack of one uniform specific marker, but the MSCs cells do express patterns of 
surface markers [99, 100]. Table 1.1, present some of the common surface molecules that 
MSCs are expressing [100], but the MSCs should also lack the expression of CD45, CD34, 
CD14, CD11b, CD79a, CD19 and HLA-DR (MHC-II) surface molecule [101].  
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Table 1.1: Some of the surface molecules expressed by MSCs, table modified from Xie 2015 [100] 
Surface molecules expressed by MSCs Other cell types expressing the surface molecule 
Stro-1 Endothelial cells 
Sca-1 HSCs, cancer stem cells 
CD13 Cancer stem cells, myeloid cells 
CD29 Neural stem cells, cancer stem cells 
CD44 T cells, cancer stem cells 
CD73 Endothelial cells, lymphocytes 
CD90 (Thy-1) T cells 
CD105 (Endoglin) HSCs, endothelial cells, macrophages 
CD106 (VCAM-1) Endothelial cells 
CD146 (MCAM) T cells, pericytes, endothelial cells 
CD166 (ALCAM) Epithelial cells 
CD271 (LNGFR) Neural stem cells, cancer stem cells 
Nestin Endothelial progenitor cells, endothelial cells, fibroblasts 
PDGFR-α (CD140a) Fibroblasts, smooth muscle cells 
Leptin-R Adipocytes 
 
In addition to their ability to differentiate into several cell types, the MSCs exhibit the 
immuno regulatory capacity of immune cells [102]. This characteristics have made these cells 
interesting in the development for treatment of immune-mediated disorders [102]. The 
immune phenotype of the MSCs is considered as non-immunogenic, characterised as MHC 
I+, MHC II-, CD40-, CD80- and CD86-, and transplantation into an allogeneic host may not 
lead to an allogeneic response [97, 102]. MSCs activated in a milieu with high levels of IFNγ, 
TNF-α, IL-1α and IL-1β have shown to stimulate the immunosuppressive mechanisms of 
MSCs, which can supress the effector functions of macrophages, neutrophils, NK cells, DCs, 
T cells and B cells (Figure 1.9) [103, 104]. Some of the secreted compounds that MSCs use 
in their function in immunosupressive mechanisms are IL-10, TGF-β, nitric oxide (NO), 
catabolites of IDO activity (i.e. kynurenine), Tumor necrosis factor-inducible gene 6 protein 
(TSG6), and prostaglandin E2 (PGE2) [103, 104]. These compounds will stimulate the 
differentiation of M2 macrophages from monocytes, which are important for tissue repair and 
have anti-inflammatory properties with its enhanced production of IL-10 and TGF-β [104]. In 
addition the MSCs will also stimulate the recruitment of monocytes and macrophages to the 
site, through their production of CCL2, CCL3 and CCL12, thus enhance the differentiation of 
more M2 macrophages [104]. With their production of catabolites of the IDO activity and 
PGE2, the MSCs will both supresses T cell proliferation (arresting in the G0/G1 phase of cell 
cycle) and favour the iTreg differentiation [104, 105]. MSCs can induce a cytokine profile 
shift in Th1-Th2 balance towards the Th2 subset of CD4+ T cells [106]. 
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Environments with weak inflammation have paradoxically shown to stimulate MSCs 
and enhance immune responses by stimulating T effector cell function and differentiation of 
the proinflammatory M1 macrophage [103, 104]. In an early phase of inflammation or during 
chronically inflammation, the proinflammatory activities of MSCs can be beneficial in 
creating a proper immune response (Figure 1.9) [104]. When MSCs are exposed to low levels 
of the proinflammatory cytokines, such as TNFα and IFNγ, they can produce the chemokines 
CXCL9, CXCL10 and CXCL11 [104]. This response is observed to occur in mice, when NO 
production is insufficient [107]. One theory of how MSC can be polarized toward 
proinflammatory or anti-inflammatory phenotypes is through their activation of TLRs, this 
process is common known as “licensing” [108]. TLR-4 and TLR-2 are toll like receptors that 
will recognize components of the bacteria wall: the lipopolysaccharide (LPS)-layer from 
gram-negative bacteria for TLR-4 activation and lipoproteins from gram-positive bacteria for 
TLR-2 activation [104, 108, 109]. Priming of TLR-4 or TLR-2 priming has shown to promote 
the proinflammatory properties of MSCs, which will start to produce of proinflammatory 
cytokines such as IL-6 and IL-8 [104, 108, 109]. Contrary, activation of TLR-3, by virus 
dsRNA, have shown to promote the anti-inflammatory properties of the MSCs [108].  
 
 
Figure 1.9: Role of MSCs in tissue repair and chronic inflammation. Recent studies on MSC-mediated immunoregulation 
suggest that MSCs are recruited to sites of tissue damage and activated by local inflammatory cytokines produced by 
activated immune cells. Depending on the types of immune responses (acute vs. chronic inflammation), MSCs may either 
attenuate the inflammatory response and lead to repair of the damaged tissue, or maintain a persistent chronic inflammatory 
response, leading to fibrosis and deformation of tissue architecture. Reused with permission from Shi et al. [110] 
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1.5.2 Mesenchymal stem cells in treatment of SLE 
With their immunosuppressive properties the MSCs have been studied as a candidate 
in therapy for autoimmune diseases such as SLE [111]. In a small pilot study from 2010 
(n=15), administration of MSCs had a positive effect in improvement of the disease [112]. 
After one year only two of the patients had relapse of proteinuria, while the rest had a 
significantly decrease in disease activity and an improvement of the levels of Treg cells [112]. 
In an article published in 2013 by Wang et.al, promising results were reported in patients with 
severe SLE (n=87) treated with MSCs derived from the bone marrow and the umbilical cord 
[113]. After 4 years of studying the clinical effects of transplantation, 50% of the treated 
patents had entered clinical remission, although 23% had suffered from disease relapse [113]. 
In a smaller study from the same research group published in 2014, 40 patients with active 
SLE got intravenously transplantation with umbilical cord MSCs on day 0 and 7. After one 
year 32,5% of the patients reported major clinical response to the treatment and 27,5% 
reported a partial clinical response, while 17,5% patients suffered with disease relapse [114]. 
In this study an improvement of the CD4+FoxP3+ Treg cell levels were observed 3 month 
after transplantation, in addition the urinary protein levels were decreased [114]. In a small 
pilot study from 2010 (n=15), administration of MSCs had a positive effect in improvement 
of the disease [112]. After one year only two of the patients had relapse of proteinuria, while 
the rest had a significantly decrease in disease activity and an improvement of the levels of 
Treg cells [112].  
In murine models of SLE, MSCs treatments have also reported in promising effects 
with suppression of immune reactions and disease recovery [115-117]. In the study published 
by Ma et.al [116], reported that MRL/lpr mice treated with murine derived MSCs had an 
increased probability of surviving compared with the untreated control group. They could also 
reported that the treated mice had smaller spleens than control animals, with fewer activated 
Th1, Th2, B cells and plasma cells, in addition to a decreased production of anti-dsDNA 
autoantibodies and proteinuria [116]. The treatment of MSCs in the murine model NZBW-F1, 
on the other hand, was shown to increase the severity of disease and stimulate anti-dsDNA 
autoantibody production [118].  After treatment the mice had increased levels of plasma cells 
in the bone marrow, increased levels of deposited glomerular immune complexes and sever 
proteinuria compared to the untreated mice [118].  
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1.6 Aim of study 
MSCs and their immunosuppressive potential have made them a excellent candidate 
for cell immune-therapy [111]. In the trials where SLE patients were treated with allogeneic 
MSCs indicated promising results such as decrease in disease severity and recovery from 
proteinuria, but there were several cases that experienced disease relapse after a short period 
of time [112-114, 119]. In murine models of SLE, MSCs treatment showed also a promising 
effect with suppression of immune reactions and disease recovery [115-117]. Other 
publications report that MSCs treatment had no effect on the clinical symptoms, such as 
proteinuria or anti-dsDNA antibody levels [118, 120]. These conflicting observations indicate 
the need for more investigation within the field of MSCs and their immunoregulatory 
properties, to evaluate the risk with treatment and make suggestions for improvement.  
Therefore the aim of this study was as follow:  
• To evaluate the immunostimulatory potential of MSCs in inflammatory environment.  
• To examine the effects of MSCs on proliferation and differentiation of CD4+ T cells, 
and how the MSC:CD4+ T cell ratio will influence their immunoregulatory effects. 
• To investigate if there were any difference in the T cell response between normal 
healthy donor, SLE patients with and without LN. 
• Determine if MSCs could play the role of LTo cells in initiating and developing of TLS   
Figure 1.10 illustrates the workflow of this study 
 
Figure 1.10: Workflow; first the immunostimulatory potential of MSCs were evaluated in a screening before their 
effect on proliferation and differentiation were examined in a coculture between MSCs CD4+ T cells isolated from 



























2 Materials and methods 
2.1 Cell work 
In this project three different cell lines were used; human mesenchymal stem cells 
(MSC, PCS-500-012, lot no: 0216, ATCC Manassas, US), human umbilical vein endothelial 
cells (HUV-EC-C, CRL-1730TM, lot no: 3822271, ATCC) and human mammary epithelial 
cells (HMLE). The HMLE cell line was a kind gift from Robert Weinberg (Whitehead 
Institute for Biomedical Research and Department of Biology, Massachusetts Institute of 
Technology). The cell lines were cultured with their appropriate media as described in Table 
2.1. In this study, the following passage number was used; passage number 9 for MSC, 
passage number 18 for HUV-EC-C and the passage number 18 for the HMLE cells.  
Table 2.1: Culture media for the cell lines  
Cell line  Basal media  Supplemented with 
MSC Mesenchymal stem cell basal 
medium (PCS-500-030, ATCC) 
Mesenchymal stem cell growth kit – for 
bone marrow derived MSCs (PCS-500-
041, ATCC). Containing L-alanyl-L-
Glutamine, FBS, rh GF-1, rhFGF-b and 
1% penicillin-streptomycin (Sigma-
Aldrich) 
HMLE 1:1 mixture of MEGM™ 
Mammary Epithelial Cell 




10ng/mL EGF 0.5 µg/mL hydrocortisone 
0,01mg/mL insulin and 1% penicillin-
streptomycin (Sigma-Aldrich) 
HUV-EC-C F-12K Kaighn´s Modification of 
Ham´s F12 media (30-2004, 
ATTC) 
0,1mg/mL of sodium heparin (H3393-
199KU, Sigma Aldich), 0,03% 
endothelial cell growth supplement 
(ECGS, E2759, Sigma Aldrich), 1% 
penicillin-streptomycin (P0781-100mL, 
Sigma-Aldrich) and 10% Fetal bovine 




2.1.1 Cell culturing 
2.1.1.1 Maintenance of cell culture and cell counting 
All procedures were performed under laminar flow hood, and all equipment were 
sterilized with 70% ethanol before starting the experiments. The different cell lines were 
grown in the appropriate medium in cell culture incubators at 37°C with 5 % CO2, 95 % air 
and 100 % humidity. Cells were grown until they reached 80% confluency.  
 
Cells passaging 
Cell culture medium was aspirated, and cells were washed once with 1×PBS 
(Dulbecco’s phosphate buffered saline, D8537-500ML, Sigma-Aldrich Corporation, US). Pre-
warmed 0.25%Trypsin-0.04% EDTA solution (T4049-100mL, Sigma-Aldrich Corporation, 
US) was added to cells in the culture flask. After 5 minutes incubation at 37°C (until 80% of 
cells were rounded up and detached), an equal volume of pre-warmed growth medium 
containing 20% FBS (7524, Sigma-Aldrich Corporation, US) were added to the flask to 
neutralize the trypsin. Cells were gently homogenized by pipetting up and down to get a 
single cell suspension. Cells were centrifuged at 250 x g for 5 minutes, and the supernatant 
was aspirated. The cell pellet was resuspended with the appropriate amount of medium and 
transferred to a new flask and incubated at 37°C inside a 5% CO2 humidified incubator. It was 
possible to calculate the cell count (Table 2.2) of the resuspended cells before they are 
transferred to the flask.  
 
Table 2.2 Equations for calculations of cell count and cell solutions with wanted cell numbers 
Eq.	1. Cell	count	
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Eq.	4. Volume	media	in	




When cells reached logarithmic growth phase (80% confluency), the culture medium 
was changed with fresh growth medium 24 hours before freezing. Cells were collected as 
describe in the Section 2.1.1.1 Maintenance of cell culture and cell counting. The cell 
pellet was resuspended in complete medium (Table 2.1) containing 20% FBS and 10% 
dimethyl sulfoxide (DMSO, D2650-100mL, Sigma-Aldrich Corporation, US) at a cell density 
of 104-106. The cryovials stored at -80oC for 24 hours and transferred into liquid nitrogen for 
long-term preservation.  
 
2.1.1.3 Thawing of cell lines 
A cryovial of cells was obtained from the liquid nitrogen storage tank, and quickly 
thawed in a 37oC incubator for 3-5 minutes. As soon as the cells were completely thawed, 
they were transferred to a 50 mL conical tube containing an appropriate volume of pre-
warmed medium inside a laminar flow hood. The cells were resuspended gently and 
transferred to the new flask and incubated at 37°C inside a 5% CO2 humidified incubator. 
Next day, the medium of the cell culture was aspirated and cells were washed once with pre-




2.1.2 Stimulation of MSCs and HUV-EC-C for co-culture 
Cells were seeded based on different experiments set up (Table 2.3) and allowed to 
grow for 24 hours. Then, cells were washed once with 1xPBS and starved with complete 
MSCs basal medium (ATCC, Table 2.1) containing 3% FBS for 18 hours. Next, cells were 
washed once with PBS and stimulated with 8ng/mL TNFα (210-TA-005, R&D systems, US) 
and IL-1β (201-LB-005, R&D systems, US) in complete media containing 0.1% FBS for 6 
hours. The stimulation setups were based on a previous study, which has been established in 
our group (RNA and molecular pathology research group, IMB, UiT).  For all the different 
setups, separate control replicates were included, where cells were starved but not stimulated.  
 
Table 2.3 Cell number of the MSCs and HUV-EC-C seeded out for the co-culture assays and the cell number of 
HMLE and HUV-EC-C seeded out as control cell lines. 
 
Number of cells seeded 
out in each well 
Type of plate used 
Volume in each 
well 
Coculture assays – 















Trans well – 
migration assay 
8000 
6 well plate 
(PLATE TYPE) 
2mL directly in well  
1mL in insert 









2.1.3 Stimulation of HMLE and HUV-EC-C cell lines in time series  
HMLE and HUV-EC-C cell lines as controls were stimulated with 8ng/mL TNFα and 
IL-1β according to the same set up as for the MSCs (Section 2.1.2) at the different time 
points; 1, 3, 6, 12, 24, 48 and 72 hours. HMLE cells were not starved before stimulation since 
complete medium did not contain FBS. After each time point, cells were washed and 
harvested with TRIsure (Section 2.8) for further analysing. 
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2.2 Patients in this study  
This study was approved by the Regional Committees for Medical and Healthy 
Research Ethics (REC; Norway, 2015/1315) .Ten patients, eighth women and two men, whit 
a diagnosis of SLE according to the criteria of the American College of Rheumatology were 
studied, and Table 2.4 present the main clinical data of these patients. Five of the patients 
were also diagnosed with lupus nephritis (LN), which was classified according to the World 
Health Organization. Patient samples were collected in 6mL sodium heparin blood tubes. The 
normal controls in this study were healthy blood donors that had donated blood for the blood 
bank at the Univeristy Hospital of North Norway (UNN), and blood form these donors were 
collected and stored as buffy coat. Employers of the UNN performed the blood sampling. 
 
2.3 Peripheral blood mononuclear cells (PBMCs) isolation  
Buffy coat or blood obtained from the blood bank (UNN) was diluted with 1xPBS + 
2%FBS (1:1). Diluted buffy coat or blood was layered gently (to minimize mixing) on top of 
Lymphoprep (1114545, STEMCELL Technologies, Canada) and centrifuged at 800 rpm for 
30 min at 15 - 25°C. Peripheral blood mononuclear cells (PBMCs) layer (grey layer, Figure 
2.1) were collected carefully without disrupting plasma and erythrocyte/granulocyte layers. 
PBMCs were resuspended in 1xPBS and centrifuged at 1200 rpm for 15 minutes. The 
supernatant was aspirated and the pellet was resuspended in appropriate working buffer 
containing 1xPBS pH 7.2, 0.5% bovine serum albumin (BSA) and 2 mM EDTA (Table 2.5) 
for further procedures. 
 







































































































RP,	Lymph	 anti-dsDNA,	LAC,	low	C3	 -	 Met,	Pred,	Pla	
P2	

































OP	 SSA,	SSB,	 -	 Pla,	Ale,	CF	
P5	
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Abbreviations Table 3.3: F.; female, M.; Male, Y.;year, md.; months, LN; Lupus nephritis, SLE; Systemic lupus 
erytheomaus, Main clinical symptoms: ANA; ANA-positive screening, Ar; Arthritis, CNS; CNS affection (epilepsy and/or 
psychosis); Discoid; Discoid Lupus erythematous (skin affections), Hem (An, Le, Ly, Tr); Haematological manifestations 
(haemolytic anaemia, leukopenia/lymfopenia, thrombocytopenia), Im; Immunological disruption, N; Nephropathy 
(protenuria >0,5g/day and/or), Ou; oral ulcers, Ph; Photosensitivity, Rash; Malar rash/Butterfly rash, Se (Pl, Pe, Ed); 
Serositis (Pleuritt, perkaritt, edokarditt). Other clinical diagnosis: APS; antiphospholipid antibody syndrome, BCC-RE; 
Basal cell carcinoma right eye, CAC; Chronic angular cheilitis, DM; Diabetes mellitus, Endo-PC; Endocrine Pancreatic 
cancer. HBP; Hypertension, HIP-OA; Hip osteoarthritis, HypoT4; Hypothyroidism, Iri; iridocyclitis, Lymph; Lymphoma, 
OP; osteoporosis, PCOS; Polycystic ovary syndrome, pre-OP; Osteopenia, PT; Partial thyroidectomy, RP; Raynaud's 
phenomenon, SICCA; Sicca symptoms, SS; Sjögrens syndrome, SSS; Secondary Sjögrens Syndrome, TB; Tuberculosis, TC; 
Thyroid cancer.  Immunological disruption: anti- indicating antibodies against the compound are found in screening, ACA-
B2-IgA; anti-B2-glykoprotein IgA, ACA-IgA; Anti-cardiolipin antibody IgA, ACA-IgG; Anti-cardiolipin antibody IgG, 
ACA-IgM; Anti-cardiolipin antibody IgM, Comp; Complement activation, LAC; lupus anticoagulant. Current therapy: 
Alby-E; Alby-E, Ale; Alendronat, Bav; Bactrim, Ben; Benlysta, CC; CellCept, CF; Calcigran Forte, Hiz; Hizentra, Hyd; 
hydroxycloroquine, Ig; tilskudd immuno-globuliner, Imu; Imurel, Kio; Kiovig, Lev; Levaxin, MabT; MabThera, Met; 
Methotrexate, Mety; Metylrednisolon, Pla; Plaquenil, Pred; Prednisolon, Pro; Prograf, Ren; Renitec, San; Sandimmun, Sen; 
Sendoxan, SM; Solu-Medrol 
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2.4 CD4+T cells isolation 
Cell numbers of mononuclear cells obtained from peripheral blood was determined, and 
cell suspension was centrifuged at 300×g for 10 minutes. The supernatant was aspirated and 
the cell pellet was resuspended in 40 µL of working buffer (containing PBS, pH 7.2, 0.5% 
BSA, 2mM EDTA) per 107 total cells. Next, 10 µL of CD4+ T Cell Biotin-Antibody Cocktail 
(130-096-533, Miltenyi Biotec, Germany) per 107 total cells was added and incubated at 4 °C 
for 5 minutes. Then, 30 µL of the working buffer and 20 µL of the CD4+ T Cell MicroBead 
Cocktail (130-096-533, Miltenyi Biotec) per 107cells were added. The cell suspensions were 
mixed well and incubated for 10 minutes at 4°C. LS MACS Columns (130-042-401, Miltenyi 
Biotec) were placed in QuadroMACS (Miltenyi Biotec) magnetic separator and rinsed with 3 
mL of working buffer. Cell suspensions were applied into the columns and flow-through 
containing unlabelled cells (representing the enriched CD4+ T cells) were collected. Through 
this method, non-target cells were magnetically labelled with the CD4+ T Cell Biotin-
Antibody Cocktail and CD4+ T Cell MicroBead Cocktail, and CD4+ T Cell were obtained by 
negative selection.  
 
Table 2.5: CD4+ Working Buffer recipe; PBS pH7.2, 0.5% BSA and 2mM EDTA 
400mL buffer 
0,5M EDTA 
20mL 10% bovine 




16 mL 20 mL 364 mL 
  
2.5 CD4+T cells co-culture  
The collected CD4+ T cells were centrifuged at 1200rpm for 10minutes at room 
temperature, and resuspended in the appropriate media. Cell suspensions with the different 
cell numbers for different experiments were prepared (see Table 2.3 and Table 2.6). The 
stimulated and non-stimulated MSCs and HUV-EC-C cells (see Section 2.1.2) were washed 
two times with 1xPBS to avoid dead cells and pre-added pro-inflammatory cytokines.  Next, 
CD4+ T cells were added based on experiments set up (Table 2.6) to each well with complete 
medium. For the trans well system, MSCs or HUV-EC-C were seeded in wells, and CD4+ T 
cells were added into the inserts (to avoid cells contact).  
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Table 2.6: Cell numbers in the experiment 
Cell number 
 Assay type Proliferation assay ½ mL in each well 
Flow measurement 
½ mL in each well 
Trans well system 
1 ½ mL in well +  
1 ½ mL in insert 






 MSC or 
HUV-EC-C	 2000	 2000	 5000	 5000	 8000	 8000	
CD4+ T-cell	 2000	 200 000	 5000	 500 000	 8000	 800 000	
 
 
2.6 Proliferation assay  
To perform a proliferation assay AlamarBlue® (ThermoFisher) was used according to 
the manufacturer’s instructions. At days zero, 5, 7, and 10, the proliferation of CD4+T cells 
co-culture with MSCs and CD4+T cells alone were measured. After transferring the CD4+T 
cells to a new flat clear bottom 24 wells plate (Corning Inc, US), 50µL of AlamarBlue (10% 
of media total volume) was added directly to the wells. Cells were incubated for three hours at 
37°C with 5% CO2. The fluorescence of reduced AlamarBlue® in the supernatant was 
measured (excitation at λ=540 nm; emission at λ=590 nm) with a CLARIOstar® (BMG 
LABTECHq).  
 
2.7 Fluorescence-activated cell sorting (FACS) of the CD4+ T cell subset  
The immunofluorescence staining of the CD4+ T cells was performed according to the 
manufacturer’s instructions. Cells were stained with antibodies against CD4, CCR4, CCR6, 
CCR10 and CXCR3 (Table 2.7).  Cell suspensions were centrifuged at 300×g for 10 minutes, 
and the supernatants were completely aspirated. The cell pellet was resuspended in 100µL of 
working buffer (containing PBS, pH 7.2, 0.5% BSA, and 2 mM EDTA). 5µL of the 
antibodies were added and incubated for 10 minutes in the dark at 4 °C. Then, cells were 
washed by adding 1 mL working buffer and were centrifuged at 300×g for 10 minutes. The 
cell pellet was resuspended in 100µL MACSQuant running buffer (130-0922-747, Miltenyi 
Biotec) and 5µL of Propodium iodide (130-093-233, Miltenyi Biotec) was added shortly 
before running the samples on the FACSARIA III (BD Biosciences).  
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2.7.1 Compensation for flow cytometry  
The compensation was performed according to the manufacturer’s instructions 
(Miltenyi Biotec). For each fluorochrome-conjugated human and mouse Igκ antibody a 
separate tube was prepared, containing 100µL of the MACSQuant Running Buffer. Next, 10 
µL of intended Igκ (human or mouse) fluorochrome-conjugated antibodies were added to the 
specified sample tube. A full drop of the MACS Comp Beads – anti-human or anti-mouse Igκ 
(Miltenyi Biotec) and a full drop of the MACS Comp Beads – Blank (Miltenyi Biotec) were 
added to each tube and incubated for 10 minutes in the dark at room temperature (21 °C) and 
tubes were shaken during incubation. Samples were diluted by adding 1mL of the 
MACSQuant Running Buffer. In the end, they were preceded on FACSARIA III to optimally 
compensate the fluorescence spillover from fluorochrome-conjugated antibodies α. 
 























































2.8 RNA isolation  
Adherent cells were washed two times with PBS and 500µL TRIsure (BIO-38033 
Bioline, London, UK) was added to the cells directly. For the non-adherent cells (Th subsets), 
cells were centrifuged at 1000xg for 10 minutes at 4oC and the supernatant was discarded and 
150µL TRIsure was added to the cells pellet. Both adherent and non-adherent cells were 
incubated 5 minutes at room temperature after adding TRIsure, and samples were collected 
and stored at -80oC. 
Further procedure of the RNA extraction was continued with phase separation by 
adding 0.2 volumes of chloroform (32211-1L, Sigma Aldrich) to each sample, and kept on ice 
for 20 minutes and shook every two minutes. Samples were centrifuged at 9000xg for 20 
minutes at 4oC, and the upper aqueous phase were collected and transferred to clean DNA-
low-bind tubes (Eppendorf, Sigma-Aldrich). The RNA was precipitated by adding 1 volume 
of isopropanol and incubated overnight at -20oC to have better participation. Next day, the 
RNA was pelleted down by centrifugation at 15000xg for 1h at 4oC. The supernatants were 
discarded and the RNA pellets were washed two times with 1mL ice-cold 80% ethanol. 
Ethanol was discarded and RNA pellets were briefly air dried and dissolved in 10 µl RNase 
free water (L0015, Merck Millipore). The RNA extraction of the HUV-EC-C cells from the 
time series set up (Section 2.1.3) was performed by using the kit Direct-zolTM RNA MiniPrep 
(R2052, Zymo Research) based on manufacture instruction. RNA quantity and quality were 
determined using the NanoDrop 2000 spectrophotometer (Thermo Scientific, US). 
  
 43 
2.9 cDNA synthesis 
High Capacity cDNA Reverse Transcription kit (4368813, Applied Biosystems® by 
Life Technologies, US) was used to synthesize cDNA. For HMLE and HUV-EC-C cell lines, 
10µL RNA sample (containing 150ng RNA in total) was used. The 2X Master mix was 
prepared based on manufacture instruction (see Table 2.8), then 10µl of The 2X Master Mix 
was added to each sample. Samples were briefly vortexed to mix solution and centrifuged to 
eliminate air bubbles. The samples were transferred to the Mastercycler gradient (5331-01627, 
Eppendorf, Germany), which was programmed for the optimal conditions for reverse 
transcription according to the manufacturer (Table 2.9). In the end, samples were diluted 1:10 
in RNase-free water and stored at -20oC. Two negative controls were also prepared, one 
minus template and one minus reverse transcriptase enzyme to evaluate procedure accuracy. 
 
Table 2.8: 2x Reverse Transcription Master Mix. The volumes are given for 1 reaction and were multiplied with the 
total number of samples that was run each time the cDNA synthesis was performed. 














each sample 2,0µL 2,0µL 0,8µL 1,0µL 4,2µL 10,0µL 
RT negative 
control 2,0µL 2,0µL 0,8µL 0 µL 5,2µL 10,0µL 
 
Table 2.9: Settings for the Therminal cycler used in the cDNA synthesis. The total reaction volume was 20µL and the 
synthesis was performed in 0.5mL DNA loBind eppendorf tubes 
 Step 1 Step 2 Step 3 Step 4 
Temperature (OC) 25 37 85 4 
Time (min) 10 120 5 oo 
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2.10 Real time quantitative PCR (qPCR) 
The mRNA expressions of genes (Table 2.10) were analysed by qPCR. The master 
mix containing 5 µL of TaqMan® Fast Universal Master Mix (4352042, Applied Biosystems), 
0.5 µL of primer probe and 2 µL of RNase-free water were prepared for each reaction. 2.5µl 
of cDNA and 7.5µL of the master mix (in total 10 µl) were pipetted to 96 wells plate 
(4346906, Applied Biosystems) and the plate was sealed (MicroAmp optical adhesive film, 
4311971, Applied Biosystems) before centrifuged briefly at 10800xg for one minute. The 
plate was run on the LightCycler® Analysing machine (Roche Holding AG, Basel, 
Switzerland) with the settings as described in Table 2.11. 
 
Table 2.10: TaqMan primer probes used to analyse the gene expression by qPCR. Applied Biosystems by Thermo 
Fisher are the provider of the primer-probes. 
Gene Cat.nr Gene Cat.nr 
CCL19 HS00171149 LTβR HS00158922 
CCL20 HS00989654 PDPN HS00366766 
CXCL13 HS00757930 TBP HS00427621 
ICAM-1 HS00164932 TNFα HS00174128 
IL-1β HS00174097 VCAM-1 HS01003372 
 
 
Table 2.11: Settings for the running of qPCR in the LightCycler® Analysing machine (96system) 
Program  Temperature Duration  Ramp 
Preincubation  95oC 600sec 4,4 
2-step amplification 







Cooling  37oC 30sec  
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2.11 Immunofluorescence staining and confocal microscopy 
2.11.1 Immunofluorescence staining of a tissue section 
Immunofluorescence staining was performed on kidney cryosections (5µm in 
thickness) from (NZBxNZW) F1 mice (Table 2.12 for description of mice). Sections were 
dried at room temperature for 30 minutes and then fixed for 5 minutes in 4% 
paraformaldehyde. Sections were washed two times in 1xPBS for 5 minutes each and 
incubated with blocking serum containing 1xPBS with 10% donkey serum (AB7475, Abcam, 
UK) for 30 minutes. The sections were incubated with primary antibodies cocktail (Table 
2.13) for 30 minutes and washed two times by dipping in 1xPBS for 5 minutes each. 
Secondary antibodies plus PerCP-CyTM 5.5 mouse-anti-mouse CD45 cocktail containing 
fluorophore-conjugated antibodies was prepared by mixing the antibodies as described in 
Table 2.14. The sections were incubated with the secondary antibody cocktail for 30 minutes 
at dark and were washed two times by deeding in 1xPBS for 5 minutes each. The sections 
were carefully dried and mounted by using 20µL Mowiol (Table 2.15). For each sample, a 
negative control was prepared through the same procedure minus primarily antibodies and 
PerCP-CyTM 5.5 mouse-anti-mouse CD45 conjugated.  
 
Table 2.12: Information regaring the disease progression in (NZBW)-F1 mice studied  
Mice Age (week) Proteinuria TLS 
Young 6 1 Negative 
Anti-dsDNA Ab positive 30 1 Positive 
Proteinuric 27 4 Positive 
 
2.11.2 Laser-scanning confocal microscopy 
Laser-scanning confocal microscopy was performed on LSM780 AxioObserver (Carl 
Zeiss, Oberkochen, Germany) by using the ZEN 2012 (black edition) software. Alexa Flour 
405, Alexa Flour 488, and Alexa Flour 594 were excited at 405, 488 and 561 nm and they 
were emitted at 440, 522 and 609 nm respectively.  PerCP-CyTM 5.5 CD45.2 conjugated was 
excited at 405 nm and was emitted at 435 nm. Two different objectives i plan-Apochromat 
63×/1.4 Oil DIC M27 and i plan-Apochromat 20×/0.8 M27 were used. The same instrument 




Table 2.13: Primary antibodies and their dilutions in the primary antibody cocktail. 
Antibody 
against 
Dilution in primary 
antibody cocktail 
Host Cat. nr Manufacture 
NESTIN 1:100 Rabbit AB7659 Abcam, UK 
SCA1 1:50 Rat AB25195 Abcam, UK 
PDGFRα 1:100 Goat AF1062 R&D Systems, US 
 
 
Table 2.14: Fluorophore conjugated primary and secondary antibodies and their dilutions in the secondary antibody 








































Table 2.15: Mowiol Mounting Medium 





dH2O 0.2 M Tris pH 8.5 






2.12 Statistic analysis 
2.12.1 Statistical analysing of data generated by the qPCR; Stimulation time series of 
HUV-EC-C and HMLE cell lines  
The raw data of the gene of interest from the qPCR, given as threshold cycle number 
(Ct), was first converted into fold changes in Microsoft Excel 2011 (version 14.7.2). This was 
performed as following; the Ct mean of the reference gene (TBP) were subtracted from the Ct 
mean of the gene of interest, creating the normalized ΔCt value. The ΔCt values were further 
corrected by the average ΔCt values of the non-stimulated cultured cells at each time point, 
resulting in the ΔΔCt value. The fold change was then calculated by 2(-ΔΔCq). For the non-
stimulated cells, the ΔCt values were also normalized against the ΔCt of the 0h cells, this to 
observe any changes from the start of the stimulation.  
Statistical analyses of the differences between the mRNA expressions of the 
investigated genes were performed in Graph Pad Prism 7 (version 7.0b). Missing values were 
handled with the average and standard error of each time point within the two groups 
(stimulated and non-stimulated/control) were calculated together with the number of 
measured values in the actual time point. To find statistical significant effects of the cytokine 
stimulation and the time of stimulation, two-way ANOVA was performed on the datasets. 
Further Sidak’s multiple comparison tests was used to compare the fold change at a given 
time point between the stimulated group and control group, and Dunnett’s multiple 
comparison test was used to compare the changes from 0h in fold changes within a group. 
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2.12.2 Statistical analysing of data generated on proliferation and differentiation of T 
cells in coculture  
Figure 2.2 present the grouping system over the data produced of T cells cocultured 
with MSCs. CD4+ T cells isolated from the main groups: healthy (n=5), SLE (n=5) and LN 
(n=5), were cultured under three main conditions: alone (T cell), in coculture with stimulated 
and non-stimulated MSCs. In addition the effects of the different ratio of MSCs on CD4+ T 
cells were evaluated, with T cells either cocultured in a low ratio (1:100, MSCs:CD4+Tcells) 
or high ratio (1:1, MSCs:CD4+Tcells). The changes in T cell proliferation were examined by 
the Alamar Blue proliferation assay, where the T cell proliferation was measured as optical 
density (OD) at day 0, day 5, day 7 and day 10.  To analyse the statistical significant effects 
provided by the time and coculture two-way ANOVA and the post-hoc analyses of Dunnett’s 
and Tukey’s multiple comparison tests were performed. Flow cytometry technique was used 
to measure the CD4+ T cells differentiation to different Th cells subsets in coculture with 
MSCs at day 10. The CD4+ T cells differentiation was examined to be either contact 
depended or not by applying a Transwell system, which prohibited direct contact between T 
cells and MSCs (nhealthy=3, nsick=3). As control cell line, the same experiment was performed 
by HUV-EC-C cells (endothelial cells) to compare with MSCs (n=3). Statistical analyses of 
the differences between the proliferations and differentiation of the cocultured T cells were 
performed in Graph Pad Prism 7 (version 7.0b). Missing values were handled with the 
average and standard error of each time point within the tree culture conditions (T cells alone, 
cocultured with stimulated MSCs, cocultured with non-stimulated MSCs).  
 
Figure 2.2: Overview over the grouping system that includes the main groups the T cells were isolated from, which 
culture condition and ratio with MSCs the T cells were cultured in. For the culture condition “T cells alone” the 1:1 and 
1:100 cell ratio refer to the matching T cell number as for the cocultured T cells.  *Duration of coculture* indicate for when 
T cells were harvested for measurement. For the proliferation assay, the T cell proliferation was measured at before culturing 
(day 0) and after five, seven and ten days after start of culturing. The measurement of Th subset with flow cytometry 




Duration of culture 
condtion  
Main group  Healthy, SLE, LN  
0, 5, 7, 10 days* 









Figure 3.1: Expression of A.] TNFα , B.] IL-1β, C.] CCL19, D.] ICAM-1 and E.] VCAM-1 in MSC stimulated by 
8ng/mL TNFα  and IL-1β  for 6h, 12h, 24h, 48h and 72h.  Data reported as mean with SEM. Two-way ANOVA was 
performed with the post-hoc analysis of Sidak’s multiple comparison test (to compare between the groups at given time 
point – marked with *) and Dunnett’s multiple comparison test (to compare within a group towards time point 0h – 
marked with #). Only statistical significant values are included in the figures and marked with either “*” or “#” where: 
*/# equals a p-value <0.05, **/## equals a p-value <0.01, *** /### equals a p-value <0.001 and ****/#### equals a p-
value <0.0001. This unpublished result is a part of a pilot study performed in the research group RAMP by my co-
supervisor. 
3 Results 
3.1 Gene expression of control cell lines  
To study under which inflammatory conditions MSCs could function as a stimulator 
of the immune system, a screening were performed. In this screening MSCs were stimulated 
with various combination of cytokines at different time points, to examine the optimal 
conditions for these cells. By combining low concentration (8ng/mL) of the proinflammatory 
cytokines TNFα and IL-1β, the immune-stimulatory characteristics of the MSCs were more 
potent MSCs significantly increased the expression of TNFα, IL-1β, CCL-19, ICAM-1 and 
VCAM-1 as presented in Figure 3.1. CCL19, ICAM-1 and VCAM-1 had their peak in 
mRNA expression after 6hour with stimulation, therefore this time with stimulation was used 
in the coculture between MSCs and CD4+ T cells. In the first phases of screening, when only 
one cytokine were used: the LTβR and PDPN were expressed for both stimulated and non-
stimulated MSCs with relatively high Ct values, but the expressions were not affected by the 
stimulation (data not shown). (My co-supervisor performed this screening before I started 
with my master project).  
The cell lines, HMLE and HUV-EC-C, were cultured in 24 well plates and stimulated 
with a combination of 8ng/mL TNFα and IL-1β. The cells were stimulated for 0, 1, 3, 6, 12, 
24, 48 and 72 hours before they were harvested.  
 
  















































































































































Controls at different time points
 50 
3.1.1 Stimulation of HMLE  
An increase in the mRNA expression of IL-1β, TNFα and ICAM-1, represented as 
fold changes, were observed in HMLE cells upon cytokine stimulation with 8ng/mL of TNFα 
and IL-1β (Figure 3.2), but they did not express CCL19, CXCL13 and VCAM-1 as no 
mRNA were detected by qPCR (data not shown).  The results of the statistical analysis of the 
fold changes by two-way ANOVA are shown in Table 3.1 for HMLE cells. Two-way 
ANOVA was conducted to examine both the individually and combined effects of stimulation 
and time on the fold change of the mRNA expression of the gene of interest in the HMLE 
cells (Table 3.1). Stimulation, time and the interaction statistical significantly influenced the 
expression of IL-1B and TNFα in HMLE cells, while the expression of ICAM-1 was affected 
by stimulation alone inducing a statistical significant effect. 
Figure 3.2: mRNA expression of IL-1β(A), TNFα(B) and ICAM-1(C) in HMLE cells stimulated by 8ng/mL of TNFα  
and IL-1β  and harvested after 0h, 1h, 3h, 6h, 12h, 24h, 48h and 72h after stimulation. Two-way ANOVA was 
performed with the post-hoc analysis of Sidak’s multiple comparison test (to compare between the groups at given time point 
– marked with *) and Dunnett’s multiple comparison test (to compare within a group towards time point 0h – marked with 
#). Data reported as mean with SEM, only statistical significant values are reported. A.] mRNA expression of IL-1β: 
Sidak’s multiple comparison test: 1h (p=0.0006), 3h(p=0.0107), 12h(p=0.0388) and 24h (0.0009). Dunnett’s multiple 
comparison test: 1h (p=0.0016), 3h(p=0.0093) and 24h (p=0.0025). B.] mRNA expression of TNFα  Sidak’s multiple 
comparison test:1h (p=0.0003), 3h(p=0.0072), 24h(p=0.0182), 48h(p<0.0001) and after 72h(p<0.0001). Dunnett’s multiple 
comparison test: 1h (p=0.0010), 3h(p=0.0094), 24h (p=0.0299), 48h (p<0.0001) and 72h (p<0.0001).  C.] mRNA expression 
of ICAM-1: Sidak’s multiple comparison test:1h (p=0.0026) and 3h(p=0.0118). Dunnett’s multiple comparison test: 1h 
(p=0.0023), 3h(p=0.0099) D-F] Controls normalized to the 0h fold change for the expression of IL-1β  (D), TNFα  (E) 
and ICAM-1 (F).  
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Performing the post-hoc analyses, Sidak’s multiple comparison test and Dunnett’s 
multiple comparison test, after the 2-way ANOVA test gave the opportunity to compare the 
expression of the gene of interest in the stimulated cells at each time point compared to the 
non-stimulated control cells and to the 0h control. The expression of IL-1β had an 
immediately increase upon stimulation with the fold change around 8 at the 1h time point, a 
bit less at 3h, but still significant. At the 6h time expression decreased and the difference 
became statistical insignificant with the non-stimulated expression with a fold change around 
2 (Figure 3.2.A). At the 12h time point, the expression increased in stimulated cells and it 
was statistically significant compared non-stimulated group with a fold change 5 in the 
stimulated group (p=0.0388). Increase in expression was continued until the 24h time point, 
but at the 48h time point, no statistical differences was observed compared to the 0h time 
point with a fold change of 2.884. The expression pattern of TNFα in the stimulated cells 
showed a statistically significant increase after one-hour stimulation (fold change of 7.735) 
and it decreased slightly at the 6h and 12h time point. The expression started to increase and 
became statistically significant at 24h time point with a fold change around 6 (Figure 3.2.B). 
The ICAM-1 expression (Figure 3.2.C) had an immediate statistically significant increase 
after one hour with a fold change of 4.872 and a decrease at the 6h time point (1.263). The 
ICAM-1 expression was slightly increased at the 12h time point (fold change: 1.990), but it 
was not statistically significant.   
 










 p= 0,0332 (*) 
F(7, 28) = 11,00 
p<0.0001 (****) 
F(7, 29) = 2,264  
p=0.0574 (ns) 
 
Time  F(7,29)=2.708 
p=0.0274 (*) 
F(7, 28) = 10,91 
p<0.0001 (****) 
F(7, 29) = 2,336  
p=0.0509 (ns) 
Stimulation F(1, 29) =49.42 
p<0.0001 (****) 
F(1, 28) = 124,3 
p<0.0001 (****) 







3.1.2 HUV-EC-C cells 
The HUV-EC-C cells stimulated with 8ng/mL of TNFα and IL-1β showed an 
increased in the mRNA expression as fold changes of IL-1β, TNFα, ICAM-1 and VCAM-1 
as presented in Figure 3.3.  The expression of LTβR in HUV-EC-C cells was not affected by 
the TNFα and IL-1β stimulation (Figure 3.3.E), but the Ct-values for LTβR for both 
stimulated and non-stimulated HUV-EC-C cells were relatively high compared to the 
reference gene (see appendix, Fig. A) indicating a relatively high and unchanged expression. 
The results of the statistical analysis of the fold changes by two-way ANOVA are shown in 
Table 3.2. No mRNA expression of CCL19, CCL21, CXCL13 and PDPN were observed 
when HUV-EC-C cell line was stimulated by 8ng/mL IL-1β and TNFα.  
A two-way ANOVA performed on the HUV-EC-C cells, showed that the individual 
effects of time, stimulation and the combined effect would give a statistically significant 
increase in mRNA expression of IL-1β, TNFα, ICAM-1, and VCAM-1 (p<0.0001) (Table 
3.2). The expression of LTβR was influenced by the stimulation alone (F(7,32)=7,092, 
p=0,0120), but neither the time alone nor the interaction between time and stimulation gave 
any statistically significant effect. 
The Sidak’s multiple comparison test showed a statistical significant increase of 
mRNA expression of IL-1β in the stimulated cells after 3h compared to the control cells (non-
stimulated) with an fold change around 52 (p=0.0221). The increase in IL-1β expression 
continues with an approximate 415 fold change after 72 hours (Figure 3.2.A). Comparing the 
mRNA expression of TNFα between the stimulated and control cells, and the expression of 
TNFα within the stimulated cells, showed that there were only statistically significant 
differences between the stimulated and control cells at 3h, 6h and 12h time points (Figure 
3.2.B).  The peak of TNFα mRNA expression occurred after 3hours with a fold change 
around 40 (p<0.0001), and expression decreased and became statistical insignificant at 24 
hours with a fold change of 6,606 compared to the non-stimulated cells (p=0.4226) and the 0h 




Figure 3.3: mRNA expression of IL-1β  (A), TNFα  (B), ICAM-1 (C), VCAM-1 (D) and LTβR (E) given as fold 
changes  (mean with SEM) in HUV-EC-C cells stimulated by 8ng/mL of TNFα  and IL-1β  and harvested after 0, 1, 3, 
6, 12, 24, 48 and 72hours (h. Two-way ANOVA was performed with the post-hoc analysis of Sidak’s multiple comparison 
test (to compare between the groups at given time point – marked with *) and Dunnett’s multiple comparison test (to 
compare within a group towards time point 0h – marked with #). Data reported as mean with SEM, only statistical significant 
values are reported. A.] mRNA expression of IL-1β: Sidak’s multiple comparison test: 3h (p=0.031), 6h(p<0.0001), 
12h(p<0.0001), 24h(p<0.0001), 48h(p<0.0001), and 72h(p<0.0001). Dunnett’s multiple comparison test: 3h (p=0.0221), 6h 
(p<0.0001), 12h (p<0.0001), 24h (p<0.0001), 48h(p<0.0001), and 72h(p<0.0001), B.] mRNA expression of TNFα  Sidak’s 
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multiple comparison test: 3h (p<0.0001), 6h(p<0.0001) and 12h(p<0.0001). Dunnett’s multiple comparison test: 3h 
(p=0.0001), 6h (p<0.0001), 12h (p<0.0001), C.] mRNA expression of ICAM-1: Sidak’s multiple comparison test: 3h 
(p<0.0001), 6h(p<0.0001), 12h(p<0.0001) and 24h (p<0.0001). Dunnett’s multiple comparison test: 3h (p<0.0001), 6h 
(p<0.0001), 12h (p<0.0001), 24h (p<0.0001) and 48h(p=0.0384) D.] mRNA expression of VCAM-1: Sidak’s multiple 
comparison test: 3h (p=0.031), 6h(p<0.0001), 12h(p<0.0001), 24h(p<0.0001), 48h(p=0.002), and 72h(p=0.007). Dunnett’s 
multiple comparison test: 3h (p<0.0001), 6h (p<0.0001), 12h (p<0.0001), 24h (p<0.0001), 48h(p=0.0015), and 
72h(p=0.0006), D.] mRNA expression of LTβR: Neither the Sidak’s nor Dunnett’s multiple comparison test gave a 
statistical significant changes in the mRNA expression of LTβR when stimulated with TNFα and IL-1β. F-J] Controls 
normalized to the 0h fold change for the expression of IL-1β(F), TNFα(G), ICAM-1(H), VCAM-1(I) and LTβR (J).  
 
The mRNA expressions of ICAM-1 and VCAM-1 (Figure 3.2.C & D) upon 
stimulation of HUV-EC-C cells showed a massive increase after 3hours with and fold change 
of 548 and 123.7 respectively. The peak in expression observed after 12 hours and was 
followed by a decrease at the 24h, 48h, and 72h time points There was not detected any 
statistical significant change in mRNA expression of LTβR in HUV-EC-C cells after 
stimulation in different time points (the Sidak’s and Dunnett’s multiple comparison tests on 
the stimulated and control group were performed) (Figure 3.2.E). 
 
Table 3.2: Results of the two-way ANOVA of the mRNA expression given as fold changes of IL-1β , TNFα , ICAM-1, 













F(7,32) = 78,63  
p<0,0001 
(****) 
F(7,32) = 23,04  
p<0,0001 
(****) 
F(7,32) = 71,24  
p<0,0001 
(****) 
F(7,32) = 159  
p<0,0001 
(****) 
F(7,32) = 0,9405 
p=0,4897 (ns) 
Time  F(7,32) = 78,50 
p<0,0001 
(****) 
F(7,32) = 23,03  
p<0,0001 
(****) 
F(7,32) = 71,24  
p<0,0001 
(****) 
F(7,32) = 159  
p<0,0001 
(****) 
F(7,32) = 0,9752  
p=0,4659 (ns) 
Stimulation F(1,32) = 727  
p<0,0001 
(****) 
F(1,32) = 143  
p<0,0001 
(****) 
F(1,32) = 465,2  
p<0,0001 
(****) 








3.2 Effects of MSC on the CD4+Tcells differentiation and proliferation 
CD4+ T cells isolated from the main groups: healthy (n=5), SLE (n=5) and LN (n=5), 
were cultured under three main conditions: alone (Tcell), in coculture with stimulated and 
non-stimulated MSCs. In addition the effects of the different ratio of MSCs on CD4+ T cells 
were evaluated, with MSCs cells either cocultured in a high ratio (1:100, MSCs:CD4+Tcells) 
or low ratio (1:1, MSCs:CD4+Tcells). The changes in T cell proliferation were examined by 
the Alamar Blue proliferation assay, where the T cell proliferation was measured as optical 
density (OD) at day 0, day 5, day 7 and day 10. Flow cytometry technique was used to 
measure the CD4+ T cells differentiation to different Th cells subsets in coculture with MSCs 
at day 10. As control cell line, the same experiment was performed by HUV-EC-C cells 
(endothelial cells) to compare with MSCs (n=3). 
 
3.2.1 The positive effects of stimulated MSCs on CD4+ T cell proliferation. 
To find the effect of MSCs on the proliferation of CD4+ T cells isolated from healthy 
blood donors, SLE- and LN patients, a proliferation assay was performed. Figure 3.4 present 
the data related to the proliferation of T cells from three groups (Healthy, SLE, and LN), 
cocultured under the three conditions: T cell alone, in coculture with stimulated MSCs and 
coculture with non-stimulated MSCs. Two-way ANOVA was performed, which gave an 
examination over the effects provided by both time and coculture individually and combined 
had on the proliferation (Table 3.3). First, the post-hoc analysis with Tukey’s multiple 
comparison test was applied to examine statistical differences between the culture conditions 
of the CD4+ T cells, then Dunnett’s multiple comparison test was used to test if there were 
any statistical significant changes in proliferation compared to the day 0.  
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Figure 3.4: Proliferation of CD4+ T cells isolated from healthy blood donors (A, D), LN patients (B, E) and SLE 
patients (C, F) in coculture with MSC at 1:100 or 1:1 ratio. The T cells were either cultured alone (Tcell – dark blue) or in 
coculture with MSC, which were either stimulated (Stim – turquoise) or not stimulated (Non-stim, pink) before coculture. 
Two way ANOVA and the post-hoc analyses Dunnett’s (#) and Tukey’s (*) multiple comparison tests were performed, to 
test for differences between the proliferation at the different days to D0 within one group and to test for differences between 
the different group at a given time point respectively. Data reported as mean with SEM. Only statistical significant values are 
included in the figures and marked with either “*” or “#” where: */# equals a p-value <0.05, **/## equals a p-value <0.01, 
*** /### equals a p-value <0.001 and ****/#### equals a p-value <0.0001. In addition the statistical significant values are 
colour coded, where turquoise marks and pink marks are for cocultured with simulated MSCs and non-stimulated MSCs 
respectively. Blue marks indicate comparison of T cell proliferation between T cells in coculture with stimulated MSCs and 
non-stimulated MSCs. See appendix Table B to Table D for adjusted p-values. OD; optical density. 
 
MSC cocultured with high ratio MSCs:CD4+ T cells (1:100 ratio), had positive effects  
on the T cell proliferation.  This was observed with an increased T cell proliferation when the 
T cells were in coculture with MSCs compared to when they were cultured alone (Figure 
3.4.A/C/E). Statistical analysis with the two-way ANOVA showed that both coculture and 
time individually and combined had a positive effect on the T cell proliferation (Table 3.3), 
when the T cells were cocultured with high ratio MSCs:CD4+ T cells (1:100 ratio).  
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Table 3.3: ANOVA table for the two-way ANOVA performed on the T cell proliferation from the three main groups  
 1:1 1:100 



























































The results from the post-hoc analyses gave that T cells isolated from healthy donors 
and cocultured in high ratio (1:100) with MSC had after five days a statistical significant 
increase when compared to T cells cultured alone (Figure 3.4.A). The proliferation of these 
healthy T cells in coculture continued to increase, and at day 7, in coculture, there was also a 
statistical significant difference between the proliferation compare to the day 0. At the day 10, 
the proliferations difference between T cells cocultured with stimulated MSCs and non-
stimulated MSCs were observed, and it was statically significant (p <0.0001).  
The effects of the MSCs were similar to the T cells isolated from SLE patients (1:100) 
as for the effects observed with the T cells isolated from the healthy blood donors (Figure 
3.4.C). T cells at day 7 proliferated statistically significant in the cocultured compared to T 
cells cultured alone, and at day 10 there were a statistical significant increase in proliferation 
of T cells cocultured with stimulated MSCs compared to the T cells cocultured with non-
stimulated MSCs (p=0.0003). The proliferation of the T cells isolated from the LN patients 
was increased when cocultured with a high MSCs: CD4+ T cells ratio (1:100) (Figure 3.4.E), 
but we did not observed statistical significant difference between the T cells cocultured with 
stimulated and non-stimulated MSCs at the day 10 (ratio 1:100).   
When MSCs were cocultured with a low number of T cells (1:1 ratio), only time had a 
statistical significant influence on the T cell proliferation for all three groups (T cells cultured 
alone, T cells cocultured with stimulated and non-stimulated MSCs) at day 10 (Table 3.3). As 
showed in Figure 3.4.B/D/F, the proliferation of the T cells isolated from healthy (B), SLE 
patients (D) and LN patients (F), had no statistical significant differences by the post-hoc 
analyses between the three culture conditions for the T cells at 1:1 ratio.  
T cells proliferation related to stimulated-MSCs:CD4+ T-cells 1:100 ratio for all 
individuals in SLE and LN groups were plotted (Figure 3.5). In the SLE group, all patients 
until day 7 showed same proliferation pattern, but at day 10, they showed different 
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proliferation pattern (some higher and some lower) (Figure 3.5.A). We did not see the same 
pattern in LN group and there were a larger variance between the patients (Figure 3.5.B) 
T cells cultured alone (both 1.1 and 1:100 ratios) from the three main groups plotted 
together, and all 15 patients from three groups showed the same proliferation pattern and no 
statically significant differences were observed between the groups (Figure 3.6). 
 




Figure 3.6: Proliferation assay of CD4+ T cells isolated from healthy blood donors, LN patients and SLE patients and 
cultured alone. A.] T cell cultured alone for the 1:100 coculture setup and B.] T cells cultured alone for the 1:1 
coculture setup. 
 
3.2.2 Effects of HUV-EC-C cells on the proliferation of the CD4+ T cells from healthy 
blood donors.  
To examine the effect of HUV-EC-C cells on T cell proliferation, CD4+ T cells were 
isolated from healthy individuals and cocultured with a low ratio of HUV-EC-C cells: CD4+ 
T cells (1:1 ratio) and a high ratio of HUV-EC-C cells:CD4+ T cells (1:100 ratio).  The 
results from the two-way ANOVA analysis showed that both coculture and time individually 
and combined have statistical significant effects on the proliferation of the T cells cocultured 
in a low ratio (1:100) (Table 3.4).  When the T cells are cocultured in 1:1 ratio with HUV-
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EC-C cells, only time will have a statistical significant effect on the T cell proliferation 
(Table 3.4).   
 The post hoc analyses of the proliferation of the T cells showed that the coculture in 
1:100 ratio were increased from day 5 when compared to the T cells cultured alone (Figure 
3.7.A). We did not observe a statically significant difference in T cells proliferation 
cocultured with stimulated HUV-EC-C cells compered to non-stimulated at day 10. When the 
T cells were cultured at 1:1 ratio, no statistically significant differences was observed by the 
post-hoc analyses between three culture conditions (Figure 3.7.B), but there were statistical 
significant differences between the day 0 and day 10 for all culture conditions of T cells. 
 
Table 3.4: Two-way ANOVA of the proliferation assay of CD4+ T cells in coculture with HUV-EC-C.  
 HUV-EC-C 1:1 HUV-EC-C 1:100 
Interaction 
(time*coculture) 
F (6, 24) = 0,1080  
p = 0,9947(ns) 
F (6, 24) = 15,10 
p < 0.0001 (****) 
Time F (3, 24) = 14,54  
p < 0.001 (****) 
F (3, 24) = 53,99 
p < 0.0001 (****) 
Coculture F (2, 24) = 0,2329  
p = 0,7940 (ns) 
F (2, 24) = 60,35 




Figure 3.7 Proliferation of CD4+ T cells isolated from healthy blood donors in coculture with HUV-EC-C in 1:00 (A) 
and 1:1 (B) ratios. The T cells where either cultured alone (T cell – dark blue) or in coculture with HUV-EC-C, which were 
either stimulated with IL-1β and TNFα (Stim – turquoise) or non-stimulated (non-Stim – pink). Two way ANOVA and the 
post-hoc analyses Dunnett’s (#) and Tukey’s (*) multiple comparison tests were performed, to test for differences between 
the proliferation at the different days to D0 within one group and to test for differences between the different group at a given 
time point respectively.. Data reported as mean with SEM. Only statistical significant values are included in the figures and 
marked with either “*” or “#” where: */# equals a p-value <0.05, **/## equals a p-value <0.01, *** /### equals a p-value 
<0.001 and ****/#### equals a p-value <0.0001. In addition the statistical significant values are colour coded, where 
turquoise marks and pink marks are for cocultured with simulated MSCs and non-stimulated MSCs respectively. See 
appendix Table E for adjusted p-values. OD; optical density. 
 



































3.2.3 Flow cytometric analysis of CD4+ Th subsets 
Figure 3.7 present the positive compensation of the gating system, which was applied 
in this study. Single cells were identified by FSC-A vs. FSC-H blots (Figure 3.8.A). After 
gating on live T cells (PI negative cells, Figure 3.8.B), CD4+Th subsets were identified by 
CD4+T cells vs. SSC-A blot (vio-green positive, Figure 3.8.C). The CD4+T cells were 
analysed for CXCR3 and CCR4 expression (Figure 3.8.D). The CXCR3 positive cells from 
Figure 3.8.D were gated and further analysed with their expression of CCR6 and CCR10 
(Figure 3.8.E), which will determine if the cells belonged to the Th1 or Th17 subpopulation.  
From Figure 3.8.D, where expression CXCR3 and CCR4 were plotted against each other, 
CCR4 positive cells were gated and further analysed in Figure 3.8.F to distinguish Th2 cells 
from the Th1/Th17 population. The CD4+ cells were also analysed for CCR4 and CCR6 
expression to distinguish Th9 cells (Figure 3.8.G). Th22 cells were detected by CXCR3 vs. 
CCR10 plot (Figure 3.8.H). 
 
Figure 3.8: Positive control gating strategy for CD4+ Th subsets population.  
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3.2.4 CD4+ T cell differentiation in coculture with MSCs 
Flow cytometry was performed to examine the CD4+ T cell differentiation in the 
coculture with MSCs. The percentage of the Th1, Th2, Th17, TH17/TH1, Th9 and the Th22 
subsets of healthy donors, SLE and LN patients are presented in Figure 3.9. Statistical 
analyses were determined by using one-way ANOVA (Table 3.5) and the Sidak’s multiple 
comparison test as post hoc analysis.  The different culture set up for the CD4+ T cells were 
only statistical significant for the T cells isolated form healthy group for Th2 and Th17 
subsets, when CD4+ T cell were cocultured with stimulated MSCs a 1:100 ratio at day 10 
compared to the day 0 and CD4+ T cells cultured alone at day 10 at 1:100 ratio (Figure 3.9.B 
& C). For the rest of the Th subsets in all three groups, only non-statistical significant trends 
were observed. For example, the Th2 subset showed a trend for the SLE group with increase 
level at day 10 for cocultured with stimulated MSCs at 1:100 ratio compared to the day 0 and 
CD4+ T cells cultured alone at day 10 at 1:100 ratio.  
 
To examine the variation in the Th subsets between the healthy, SLE and LN group, 
the levels of the various subsets at day 0 were compared between the groups. One-way 
ANOVA showed that there were only statistical significant differences for Th1 and Th9 
subsets at day 0 in the SLE group compared with the healthy group. Both subsets were lower 
in the SLE group compared to the healthy group (Figure 3.10.A & E).  For the LN group, a 
trend with higher levels of Th2 and Th17 were observed, but the differences were not 








Figure 3.9:  Th subsets (from healthy donors, and SLE and LN patients) differentiation in coculture with MSCs. 
Abbreviations; T cells from day 0 (D0), T cells grown alone for ten days (T), T cells grown in coculture with MSCs 
pre-stimulated for 6hours with TNFα  and IL-1β(S), T cells grown in coculture with non-stimulated MSCs (N). Data 
are presented as mean with SEM. One-way ANOVA and the post-hoc analysis Sidak’s multiple comparison tests were 
performed on the Th-cell subsets within each group (Healthy, SLE or LN). A.] Th1 subset; B.] Th2 subset; statistical 
significant differences observed for the healthy group between the T cells at day 0 (D0) and T cells from coculture with pre-
stimulated MSC (S) (p=0.0373), and between T cells cultured alone at day 10 (DT) and T cells from coculture with pre-
stimulated MSC (S) (p=0.0462). C.] Th17 subset; statistical significant differences occurred only for the healthy group 
between the T cells at day 0 (D0) and T cells from coculture with pre-stimulated MSC (S) (p=0.0224). D.] Th1/Th17 subset; 





















































































































































































Table 3.5: One-way ANOVA results of the changes in Th subset populations upon coculture with stimulated or non-
stimulated MSCs.  
 Healthy 1:100  SLE 1:100  LN 1:100 
Th1 
F(3, 16)=1.575  
p=0.2345 (ns) 
 F(3, 16)=0.1878  
p=0.9031 (ns) 
 F(3, 16)=0,1653  
p=0,9182 (ns) 
Th2 
F(3, 16)=4.259  
p=0.0217 (*) 
 F(3, 16)=0.5540  
p=0.6528 (ns) 
 F(3, 16)=0.3277 
p=0.8054 (ns) 
Th9 
F(3, 16)=0.4930  
p=0.6922 (ns) 






F(3, 16)=3.955  
p=0.0276 (*) 
 F(3, 16)=0.6463  
p=0.5965 (ns) 
 F(3, 16)=0.1580 
p=0.9230 (ns) 
Th22 
F(3, 16)=1.103  
p=0.3766 (ns) 
 F(3, 16)=1.707  
p=0.2057 (ns) 
 F(3, 16)=1.915  
p=0.1679 (ns) 
TH1/Th17 
F(3, 16)=0.3350  
p=0.8002 (ns) 
 F(3, 16)=1.142  
p=0.3624 (ns) 





Figure 3.10: Th subsets from healthy donors, and SLE and LN patients at day 0. One way ANOVA and the post-hoc 
analysis Sidak’s multiple comparison tests were performed on the Th-cell subsets within each group (Healthy, SLE or LN) 
Statistical significant values are marked with  “*” where: * equals a p-value <0.05, ** equals a p-value <0.01 and *** 
equals a p-value <0.001.A.] Th1 subset; there were significant statistical differences between the levels of Th1 from healthy 
blood donors and Th1 from SLE patients (p=0.0449). B.] Th2 subset; C.] Th17 subset; D.] Th1/Th17 subset, E.] Th9 
subset; there were significant statistical differences between the levels of Th1 from healthy blood donors and Th1 from SLE 








































































































































































To determine if the differentiation of Th subsets were depended on direct contact with 
MSCs or not, a Transwell system were used (Figure 3.11). The results showed that Th2 and 
Th17 subsets differentiation were contact dependent since no statistically significant changes 
were observed at 1:100 ratios, especially in the healthy group (Figure 3.11). Further, the 
different Th subset populations in Transwell system were compared with T cells in direct 
contact with MSCs at 1:100 ratios (Figure 3.12). 
 
 
Figure 3.11: Th subset differentiation in T cells obtained from health blood donors (n=3) and patients (n SLE=1, n 
LN= 2), when Transwell system were applied to the culture condition.  T cells from day 0 (D0), T cells grown alone for 
ten days (T), T cells grown in coculture with MSCs pre-stimulated for 6hours with TNFα and IL-1β(S), T cells grown in 
coculture with non-stimulated MSCs (N). Data are presented as mean with SEM. Only statistical significant values are 
included in the figures and marked with either “*”, where: *equals a p-value <0.05, **equals a p-value <0.01, *** /equals a 
p-value <0.001 and **** equals a p-value <0.0001. A.] Th1 subset, B.] Th2 subset, C.] Th17 subset, D.]Th1/Th17 subset, 
E.]Th9 Subset, F.] Th22 subset 
 
 




































































































































































Figure 3.12: Comparison of the Th subsets when the T cells are cocultured with MSCs. Data is presented as 
mean with SEM. One-way ANOVA and the post-hoc analysis Sidak’s multiple comparison test were performed 
on the Th-cell subsets, which CD4+ T cells were cocultured in direct contact with MSCs or in Transwell system. In 
the post-hoc analysis following comparison were performed; T cells cocultured in direct contact with stimulated 
MSCs compared with T cells cocultured with stimulated MSCs in Transwell system (light blue); T cells cocultured 
in direct contact with non-stimulated MSCs compared with T cells cocultured with non-stimulated MSCs in 
Transwell system (dark blue); T cells cultured alone for the direct contact setup compared with T cells cultured 
alone for the Transwell system (purple). A.] and B.] present the changes in respectively Th2 and Th17 subset 
populations, when T cells from healthy blood donors were cocultured in direct contact or in Transwell 
system with MSCs. The marked statistical significant with an increase levels of Th2 and Th17 population, when 
the T cells from healthy blood donors were cocultured in direct contact with MSCs, were based on the calculation 
in Figure 3.8. C.] and D.]Changes in Th2 and Th17 subset populations for when T cells from patients are 
cultured with MSCs, either in direct contact or in Transwell system. One-way ANOVA and Sidak’s multiple 
comparison test showed statistical reduction in Th17 population for T cells cultured alone in the Transwell system, 
compared to the T cells from SLE patients and cultured without the Transwell system (p= 0.0218). Abbreviations: 
T cells from day 0 (D0), T cells grown alone for ten days (T), T cells grown in coculture with MSCs pre-
stimulated for 6hours with TNFα and IL1β(S), T cells grown in coculture with non-stimulated MSCs (N). 
Only statistical significant values are included in the figures and marked with either “*”, where: *equals a p-value 
<0.05, **equals a p-value <0.01, *** /equals a p-value <0.001 and **** equals a p-value <0.0001 
The one-way ANOVA and the Sidak’s multiple comparisons between Th2 and Th17 
subsets from direct contact compared to the Transwell at 1:100 ratio, showed only 
significantly lower Th17 subset at day 10 for the T cells cultured alone in the Transwell 
system compared to the Th17 subset in the direct contact in SLE group at 1:100 ratio. In the 
Healthy group, Th2 and Th17 populations from cocultured with stimulated MSCs at 1:100 
ratio were higher, but not statically significant, in direct contact compared to Transwell 
system. In the SLE and LN groups, Th2 and Th17 populations in all three different setups in 
direct contact (cocultured with stimulated MSCs, cocultured with non-stimulated, and T cells 





























































































































































































3.2.5 CD4+ T cell differentiation in coculture with HUV-EC-C cells 
The same experiment was performed with HUV-EC-C cells to examine if HUV-EC-C cells 
also could induce differentiation of CD4+ T cell isolated from healthy individuals (n=3) or 
not (Figure 3.13). One-way ANOVA analysis showed that only the coculture between T cells 
with HUV-EC-C cells could only have a statistical significant effect on the Th1/Th17 subset 
population (F(3,8)=13.73,p=0.0016), but not for the remaining CD4+ subset population. 
Th1/17 subset increased significantly at day 10 in all three different setups (cocultured with 
stimulated HUV-EC-C, cocultured with non-stimulated, T cells cultured alone at 1:100 ratio) 
compared to day 0, but there was not a significant difference between cocultured with 
stimulated HUV-EC-C compared to T cells cultured alone at 1:100 ratio. 
 
Figure 3.13: Th subsets healthy donor in coculture with HUV-EC-C cell line, which were either pre-stimulated with 
TNFα  and IL-1β  (S) or were non-stimulated (N). T cells from day 0 (D0) and T cells grown alone for ten days (T).  
One way ANOVA and the post-hoc analysis Sidak’s multiple comparison tests were performed on the Th-cell subsets, and 
statistical significant values are marked with  “*” where: * equals a p-value <0.05, ** equals a p-value <0.01 and *** equals 
a p-value <0.001. A.] Th1 subset, B.] Th2 subset, C.] Th17 subset, D.] Th1/Th17 subset; Statistical significant differences 
between D0 to T (p=), D0 to N (p=) and between D0 and S (p=), E.] Th9 subset, F.] Th22 subset  
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3.2.6 Flow analysis on T cells cocultured in 1:1 ratio of MSCs 
CD4+ T cells viability among all three groups (Healthy, SLE and LN) reduce sharply 
at day 10 in 1:1 ratio  (MSCs:CD4+ T cells) coculture set up compared to 1:100 (Table 3.6). 
Due to the low number of live CD4+ T cells, we observed dramatically small cell population, 
few cells, (Figure 3.14) in different Th subsets selected populations. In some of the patients, 
only one or two cells could (e.g., Th17 in the Healthy group, Table 3.6) change the 
population percentage significantly. Hence, it is not possible to evaluate reliably the CD4+ T 
cells differentiation at 1:1 ratio. 
 
Table 3.6: Cell count and the population percentage of different CD4+ T cells subsets after cocultured with non-
stimulated MSCs at 1:1 ratio. 
  Healthy SLE LN 
Live % 11.4 2.27 14.3 
# 1674 302 1923 
Th1 % 28.1 0 7.3 
# 406 0 123 
Th2 % 0.42 0 2.31 
# 6 0 39 
Th17 % 0.21 0 2.02 
# 3 0 34 
Th9 % 22.8 40.6 12.7 
# 329 54 214 
Th1-17 % 4.64 6.77 1.6 
# 67 9 27 
Th22 % 0 1.5 0 
# 0 2 0 








3.3 Confocal of murine kidney 
Tissue specific MSC-like cells were detected in murine kidneys (NZBW-F1), which 
have been stained with immunofluorescence marked antibodies against PDGFR-α, Nestin, 
SCA-1 and CD45 (Figure 3.15). The MSC-like cells were characterized by their expression 
of PDGFR-α, Nestin and SCA-1 and lacking the expression of CD45. There were endothelial 
cells in the veins and arteries and some of the tubular cells, which were positive for Nestin 
and SCA-1, and negative for PDGFR-α and CD45. MSC-like cells were mostly located in the 
pelvic wall within the kidney from the young mice, and CD45+ tissue resident immune cells 
were observed at the edge of the pelvic wall (Figure 3.15.A). The antibody positive and 
protenuric mice had developed TLS in the pelvic wall, relatively larger in protenuric mice 
(Figure 3.15 B & C). In TLS, MSC-like cells were observed mostly in the pelvic wall and in 
between the CD45+ immune cells (Figure 3.15.B & C). Higher magnification of Region of 
Interest (ROI) are shown in Figure 3.16 combined with signal intensity indicators, and signal 
intensity graphs presented in Figure 3.17. The signal intensity indicators were located in two 
distinct areas, area 1 (higher frequency of MSC-like cells) and area 2 (higher frequency of 





Figure 3.15: IF of NZBW-F1 murine kidney from A.] Young mouse (6weeks old, Ab negative proteinuria negative), 
B.] Antibody positive mouse (30 weeks old, Ab positive, proteinuria negative), and C.] Protenuric mouse (27 weeks 
old, Ab positive, proteinuria), stained with antibodies against (2.) PDGFR-α , (3.) CD45, (4.) Nestin and (5) SCA-1. The 
arrows in the merged images (6.) are pointing on areas containing MSC-like cells (PDGFR-α, Nestin+, SCA-1+, CD45-).  
The boxes in the merged images are further presented in Figure. 3.X. Abbreviations: A; artery, Ab; dsDNA antibody G; 






Figure 3.16: Magnification of the images from the boxes in “Figure 3.X; IF of NZBW-F1 murine kidney”.  Kidney 
from A.] young mouse (6weeks old, Ab negative, proteinuria negative ), B.] Antibody positive mouse (30 weeks old, Ab 
positive, proteinuria negative), and C.] Protenuric mouse (27 weeks old, Ab positive, proteinuria), stained with 
antibodies against (1.) PDGFR-α , (2.) CD45, (3.) Nestin and (4.) SCA-1. In the merged images with the signal intensity 
graphs (6.), the numbers 1 and 2 are referring to areas with MSC-like cells (1, PDGFR-α+, Nestin+, SCA-1+) and areas 






Figure 3.17: Signal intensity graphs over the areas with areas marked with signal intensity graphs in Figure 3.16. A.1, 




4 Discussion  
In the present study we evaluated the immunostimulatory potential of MSCs and their 
effects on proliferation and differentiation of CD4+T cells. We also observed if there were 
any differences in the CD4+ T cell response in normal healthy blood donors and in SLE 
patients with and without nephritis. Based on these observations we investigated if MSCs 
could be a potential candidate as LTo cells in developing TLS.    
 
4.1 The immune-stimulatory potential of MSCs and their effects on CD4+ T 
cells in coculture 
Previous studies have assessed that MSCs can have proinflammatory properties if the 
pattern recognition receptors TLR-2 or TLR-4 are activated [104, 107, 109]. In our study we 
validated the immunostimulatory potential of these cells during inflammation, through 
resemble the conditions at the site of inflammation. By applying a screening of MSCs with 
different cytokines for various time lengths, we found the immunostimulatory potential of 
these cells were most potent in a low inflammation environment. The MSCs cultured with a 
low concentration (8ng/mL) of TNFα and IL-1β for a short period of time (6hours) presented 
inflammatory characteristics, with their enhanced production of proinflammatory cytokines, 
expression of adhesion molecules and an increased production of chemokines like CCL19, 
which is known for T cell recruitment. CCL19 is a chemokine, which is important for the 
recruitment and organization of T cells in an developing lymphoid tissue [86].  
From the stimulation of MSCs with low concentration of proinflammatory cytokines, 
we showed that these cells could initiate an early inflammatory cascade by the production of 
cytokines and chemokines. The next step in this study was to assess their effect in a coculture 
with CD4+ T cells isolated from healthy individuals, SLE patients and LN patients. The 
results from our study showed that MSCs cocultured in a low (1:1) CD4+ T cell ratio did not 
have any stimulatory influence on the T cell proliferation. While MSCs cocultured in a high 
(1:100) CD4+ T cell ratio, had an enhanced effect on proliferation and differentiation of T 
cells. 
Najar et al. [106], showed the importance of the MSCs:T cells ratio in coculture and 
how this could influence the MSCs’ immunoregulatory potential. They cocultured MSCs for 
five days in a relatively low ratio with T cells (1:4 and 1:8), and observed inhibitory effect of 
MSCs on the mitogenic T cell proliferation (the authors did not specified clearly what kind of 
T cells, CD4+ or CD8, they were using) [106]. Their results also imply that the T cell 
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proliferation will be stimulated by MSCs, if the MSCs were occulted with T cells in a high 
MSC:T cell ratio (1:80) [106]. The study by Le Blanc et al. supports this theory, which the 
ratio between MSCs and T cells in culture will influence the observed results of T cell 
proliferation [121]. By stimulating peripheral blood leukocytes in a mixed leukocyte reaction 
(MLR) before coculture they showed MCSs in a low MSC:Tcell were inhibiting the MLR, 
while MSCs in a high MSC:T cell ratio had the opposite effect and were enhancing the MLR 
[121]. Bocelli-Tyndal and colleagues also support the possible outcome of that MSCs can be 
immunostimulatory at specific conditions [122]. In their study, they stimulated PBMCs, total 
T cell population and the T cell subset (CD4+ and CD8+) with IL-2, IL-7 or IL-15, then 
cocultured with MSCs derived from the bone marrow. The PBMCs and T cells were 
cocultured from a low ratio (1:2) to a middle high ratio (1:50) for one week before the 
proliferation was measured. The PBMCs and T cells stimulated with IL-2 and IL-15 before 
cocultured and cocultured with MSCs in a 1:50 ratio (MSCs:PBMC/Tcell), had an increased 
proliferation compared to PBMC or T cells were cultured alone. However, in their study, 
there were no effects on proliferation when T cells were not stimulated before cocultured with 
MSC. In addition they did not stimulate the MSC before coculture with T cells.  
The results from our study showed that MSCs cocultured in a low (1:1) CD4+ T cell 
ratio did surprisingly not have any effect on the T cell proliferation. In the results published 
by other research groups, the low MSC:T cell ratio will promote the immuno-suppressive 
potential of MSCs and the T cell proliferation will be inhibited [106, 121, 122].  In these 
reported studies the authors did not include how the time and the stimulation alone will affect 
the proliferation of activated T cells, they did this by exclude the data from the day 0. By 
excluding those data, the accuracy of their results is open for questions.  
MSCs cocultured in a high ratio of CD4+ T cell, promoted the immunostimulatory 
potential of the MSCs and an increased proliferation of CD4+ T cells were observed for all 
three groups (healthy, SLE, LN). By stimulate the MSCs before coculture we tried to 
resemble an early inflammation environment to observe if this treatment would influence the 
observed effects on the T cell proliferation.  Stimulation of MSCs before coculture enhanced 
the proliferation of CD4+ T cells isolated from healthy blood donors and SLE patients 
without nephritis, compared with the proliferation of CD4+ T cells in coculture with non-
stimulated MSCs. For the CD4+ T cells isolated from the LN patients: the T cells 
proliferation for the CD4+ T cells cocultured with non-stimulated MSCs showed a similar 
enhanced proliferation, compared to CD4+ T cells cultured alone. This proliferation response 
of the CD4+ T cells from the LN patients can be linked to the possibility that these cells could 
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be more activated in patient’s body, based on disease activity level, compared to the CD4+ T 
cells isolated from healthy blood donors and SLE patients. We did not observe any 
differences in T cell proliferation between the three groups (healthy, SLE, LN), when the 
CD4+ T cells were cultured alone. These observations indicate that the observed 
proliferations are initiated by MSCs in the coculture, and are not a result of other factors.  
By comparing the Th-subsets from the three groups (healthy, SLE, LN) at day 0, a 
trend with higher levels of Th2 and Th17 subset were observed for the LN group. Th17 and 
their characteristic cytokine IL-17 are found to be increased in SLE patients, and even more 
during a SLE flare [123]. In the article by Saber and colleagues [124]: an correlation between 
Th17 cells levels in blood and the concentration of IL-17 in urine can be linked to nephritis in 
SLE patients and are  good markers for disease activity in LN. In lupus nephritis, 
autoantibody deposition in the kidney have a major pathological role where they will promote 
the inflammation cascade within for example the glomeruli and contribute to development of 
proteinuria. Often, the deposited autoantibodies are from the subclasses of IgG (IgG1, IgG3, 
IgG4), IgE and IgA [29, 125, 126], indicating that Th2 cells are involved in the activation of 
antibody producing plasma B cells in lupus.  
By studying how the MSCs will influence the proliferation of the CD4+ T cells 
isolated from the three groups (healthy, SLE, LN), it is possible to assume the MSCs perform 
their immunostimulatory potential and stimulate the CD4+ T cells when they are cocultured 
in a high T cell ratio. The next step was to study if this interaction between MSCs and CD4+ 
T cells could influence the Th cell population by stimulating differentiation into one or 
several Th subsets.  MSCs, which were stimulated with cytokines to resemble the 
inflammatory condition, were capable to induce Th2 and Th17 differentiation in the healthy 
group in the MSC: CD4+ T cell at ratio of 1:100 with direct contact. In addition by separating 
the CD4+ T cell from the MSCs, we could observe that the shift in CD4+ Th subset were 
contact depended, as crosstalk through Transwell system were not sufficient to initiate the 
differentiation. Duffy et al. [127] reported in 2011 that MSCs could inhibit Th17 
differentiation of CD4+ T cells in a low MSC:T cell ratio. Similar results were presented by 
Carrion and colleagues, where they had cocultured MSCs with T cells under Th1, Th17 or 
Treg polarizing conditions in 1:10 MSC:T cell ratio [111]. Controversially Rozenberg et al. 
[128] reported that MSCs could stimulate Th17 response in an coculture with PBMCs, where 
increased levels of IL-17 were observed when activated PBMCs were cocultured with MSCs 
for 3 days  (1:10, MSC:PBMC ratio). In a study by Darlington et al. [129] medium from  
MSCs cultures, where the cells were either stimulated with 5pg/mL IL-1β or kept non-
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stimulated, had the potential to supress Th1 cells and simultaneously stimulate Th17 cell 
responses. These findings from Rozenberg and Darlington support the hypothesis regarding 
the immunostimulatory properties of MSC. Under the specific conditions, MSCs can shift the 
CD4+ T cell population and promote Th17 subset response. Thereby, MSCs can promote an 
inflammation cascade and contribute to increase the severity of the disease, since the effector 
mechanisms of the Th17 subset are involved in several autoimmune diseases [130].  
Batten et al. [131] reported that in a coculture with a low MSC:PBMC ratio, MSCs 
suppressed subsequent CD4+ T cell proliferative responses to allogeneic PBMCs in a contact-
dependent manner [131]. Interestingly they also reported an increased Th2 response in the 
coculture, indicating that MSCs can promote Th2 differentiation [131]. Increased levels of 
Th2 in the blood have also been observed after MSCs transplantation in animal models of 
autoimmune diseases [132, 133]. In the animal model of multiple sclerosis, mice treated with 
MSCs transplantation could recover from limb paralysis [132]. This observed neurological 
improvement was associated with reduced infiltration of CD45+ leukocytes in the brain and 
spinal cord. The levels of Th1 and Th17 cells and their associated cytokines were reduced, 
while the IL-4 producing Th2 cells were elevated [132]. In the animal model of type 1 
diabetes, Fiorina and colleagues analysed the Th1 and Th2 cytokine patterns in immune cells 
isolated from the spleen of mice treated with MSCs for 4weeks [133]. They found that the 
treatment affected the Th effector response between Th1 and Th2 cells, observed with 
increased IL-4 and IL-10 and thereby a shift toward a Th2 profile [133]. Interestingly, none of 
these studies could report an increase in both the Th2 and Th17 profile simultaneously, as we 
observed in our study. One of the reasons might be because they were focusing on either the 
Th1/Th2 balance or Th1/Th17 balance, and not the changes in the entire CD4+ T cell 
population. Nerveless, in both of the cases, when either Th17 or Th2 effector functions were 
increased, the Th1 effector functions were decreased [128, 129, 132, 133].  
In our study we observed individually differences on the proliferation within the 
patient groups. This individually differences will interrupt the observation and overview over 
the trends that are reported in each patient group. Each patient holds his or her own unique 
disease progression and treatment, which is reflected into our results. Ideally, it would have 
been advantageous to increase the patient number in each group, for example from n=5 to 
n=10, to correct for those observed individual differences and to be able to give stronger 
statistical observations for the patients as two distinct populations.   
From the screening of MSCs with low concentrations of the proinflammatory 
cytokines IL-1β and TNFα and from the coculture between T cells isolated from three groups 
 79 
and MSCs, we have examined the immunostimulatory potential of MSCs. They have the 
capacity of stimulate CD4+ T cell proliferation and initiate CD4+ T cell differentiation into 
Th2 and Th17 subset.  We believe, it is important to consider our results before administrating 
MSCs to SLE and LN patients as cell therapy, since the MSC:T cell ratio and the local 
inflammatory environment can lead MScs to initiate and stimulate the immune response more 
severe.  
 
4.2 MSC in the role as a LTo cell in developing of TLS 
In the theory of TLS development, stromal cells with mesenchymal origin have been 
hypothesized to play the role as LTo cells. From the confocal microscopy of the kidney from 
the young mice, we observed that MSC-like cells were located in the pelvic wall before TLS 
formation start. In the TLS observed in the kidneys of the antibody positive mice and from the 
protenuric mice, the MSC-like cells were located in the pelvic wall surrounding the TLS 
structure and also in between the CD45+ immune cells.  These observations indicate that 
MSC-like cells are involved in the TLS formation and function. By merging this information 
with the observations from the coculturing with CD4+ T cells in a 1:100 ratio, it is possible to 
suggest that MSCs can play the role as LTo cells and initiates the TLS formation.  
From the literature the mesenchymal stem cells are assumed to initiate the formation 
of SLO in a developing embryo [70, 88].  The formation of SLO and TLS share several 
patterns and mechanisms, and one can assume that the mesenchymal stem cells cells also are 
important in the developed TLS [88].  In our study a possible connection between TLS 
formation and the immunostimulatory properties of MSCs, can start with the CCL19 
production. MSCs were able to produce CCL19 upon stimulation with low concentrations of 
the proinflammatory cytokines IL-1β and TNFα for a short period of time. This cytokine is 
necessary for recruitment of T and is involved in homing of T cells and DCs to lymphoid 
tissues [134], indicating that MSCs can be involved in the first phases of recruiting T cells to 
the site of inflammation. When the ratio between MSC and T cells get sufficient enough, the 
MSCs will stimulate the T cells to proliferate and initiate the T cell differentiation into 
inflammatory Th2 and Th17 subset. The Th17 will produce IL-17 and this cytokine has been 
shown to promote expression of CXCL13, CCL19 and CCL21 in tissue stromal cells, which 
are involved in the initial formation of lymphoid organs and are important in the maintenance 
of the structure [62, 135]. From the developing SLO, the first stages in lymphoid development 
were involved in recruiting of LTi cells to the site and were not depended on LTα1β2/LTβR 
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signalling [87]. In the developing TLS in the murine kidney, a crosstalk between the IL-17 
producing T cell and the MSC-like cell could then initiate the LTα1β2/LTβR signalling 
between the MSC-like cell and the CD4+ T cell and then promote initiating TLS formation 
and development. The formation of the Th2 subset of CD4+ Th cells by MSC cells, in a tissue 
can promote the developing of IgG producing B cells and induce a local production of 
antibodies that are involved in renal manifestations of lupus. In fact Th2 cells have shown to 
become Tfh-like cells in response, like what we see in helminths infections with persistence 
of pathogen/antigen conditions [136].  
 
4.3 Epithelial and endothelial cells immunostimulatory properties 
In our study stimulation of the HMLE and HUV-EC-C cell linages were used as 
control for the observed effects with stimulation of the MSC cells. By stimulating these two 
cell types, HMLE as epithelial cells and HUV-EC-C as endothelial cells, we were able to 
study whether low concentration of cytokines could have an effect on two normal cell types 
within a tissue. Ideally, it would have been optimally to use epithelial and endothelial cells 
derived directly from the kidney, for example epithelial cells from the pelvic wall or proximal 
tubule cells. However in this study the use of HMLE and HUV-EC-C cells were (as mention) 
as control cell line, in the comparison of the effects observed by the MSCs. 
 The HUV-EC-C cells had a large increase in their expression of the adhesion 
molecules VCAM-1 and ICAM-1 upon stimulation, which is a common response in activated 
endothelium [137-139]. Activated endothelium will increase their expression of adhesion 
molecules to promote leukocyte rolling and transmigration and are important for the 
recruitment and infiltration of immune cells into an inflamed tissue [139]. Both the HUV-EC-
C and the HMLE cells had an increase in their production of the pro-inflammatory cytokines 
IL-1β and TNFα, which was an expected result of positive-feedback reaction to enhance the 
inflammation response initiated by mentioned proinflammatory cytokine [137, 139]. 
With their unchanged expression of LTβR upon stimulation with low concentrations 
of proinflammatory cytokines, the HUV-EC-C cell can be a potential candidate as progenitor 
cell for HEV development. Activation of LTβR on endothelial cells are important for 
development of HEVs in SLOs [83], predicting that they can become HEVs in a developing 
TLS. The protein podoplanin (PDPN) is frequently expressed in lymphoid tissues and are 
assumed to be important for the integrity of HEVs [140, 141]. By evaluating the expression of 
PDPN in stimulated HUV-EC-C cells, we can observe if stimulation of these endothelial cells 
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can initiate the differentiation into the HEVs or other lymphoid tissue cells such as lymphatic 
endothelial cells. Since HUV-EC-C cells were not capable to express PDPN upon stimulation 
of low concentration IL-1β and TNFα, we can conclude that these cells can’t differentiate 
into lymphoid tissue cells upon stimulation of low concentration of just IL-1β and TNF-α. To 
be able to differentiate into HEVs, endothelial cells need activation through their LTβR and 
archive growth factors from an LTo cell [83].  
By using the HUV-EC-C cell line as a control for the coculture, we assessed the 
possible outcome of if endothelial cells in an inflamed tissue also could promote the changes 
in Th cells subsets population. From our results, the HUV-EC-C cells are capable to stimulate 
proliferation of healthy T cells, but will not influence the changes of the CD4+ Th subset 
population. In the stimulation of HUV-EC-C cells we observed that these cells were capable 
of producing high level of the proinflammatory cytokines IL-1β and TNFα, in addition to 
high levels of the adhesion molecules ICAM-1 and VCAM-1. These compounds might be one 
of the factors that could explain the proliferation of T cells. Endothelial cells are one of the 
first cells to interact with microbial components in the circulation and tissue damage, and will 
provide important signals for early activation of immune cells [142]. IFNγ stimulation of 
endothelial cells has been shown to promote production of compounds of the TNF family, 
which was observed with increased cytokine production and proliferation of CD4+ and CD8+ 
memory T cells [143]. In the study by Wheway et al., microparticles shed from activated 
endothelial cells were capable of stimulating both CD4+ and CD8+ T cells [144], which could 
also be one explanation of why we can observe increased CD4+ T cell proliferation in the 
coculture with HUV-EC-C cells. If HUV-EC-C cells could differentiate into HEVs in a 
developing TLS, they will also harbour an important immunostimulatory potential by 
regulating the recruitment of immune cells through their production of the chemokines 
CCL19, CCL21, CXCL12 and CXCL13 [62]. However, in our study we aimed to observe the 
effects of MSCs. The reason why we choose to work with HUV-EC-C and not HMLE as 
control for the coculture: is because of their immunological important properties as a 
messenger in an early inflammation cascade [142].   
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5 Conclusion  
Our study indicates that the MSCs are capable to trigger an inflammation reaction, 
when they are exposed to an environment with low concentrations of proinflammatory 
cytokines. These cells are capable to stimulate T cell proliferation and differentiation when 
they are cocultured with a high ratio T cell (1:100), and thereby promote the development of 
TLS as an LTo cell. These factors are important in the consideration of treatment of lupus 
patients with MSCs, and this might be one of the factors that will determine if some of the 
cases of transplantation went wrong and a relapse occurred. Further research in the fields of 
TLS formation and the immunoregulatory potential of MSCs are needed to assess the possible 
outcome and safety with MSC transplantation. 
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6 Future directions   
Further research has to be done to fill in gaps in our understanding of the 
immunostimulatory properties of MSCs and their role in TLS development. From the 
coculture between MSC and CD4+ T cells, an interesting approach to understand how these 
cells interacts will be by analysing and studying the changes in mRNA expression culturing 
has on the MSCs and the CD4+ T cells. “How will the 1:1 and 1:100 MSC-T cell ratio 
influence this mRNA expression?” is a question, which is longing for an answer. In our 
hypothesis an increased activation of LTβR and markers for FDC and FRC differentiation 
will support that the MSCs can function as an LTo cell.  
Another approach is to study the media from the coculture for soluble proteins and 
cytokines. Are there any differences in the compensations of the media collected from the 
coculture with CD4+T cells in 1:1 or 1:100 ratios, and will stimulation of MSCs before 
coculture influence this compensation of the media? Can we transfer the media from the 
MSC:T cell coculture to cultured B cells, and how will this influence the B cell response?  
A third possible approach in the study of the TLS development is to analyse the 
mRNA expression of the HUV-EC-C cells from the CD4+T cell coculture. Can these 
endothelial cells begin their journey towards HEV differentiation when in coculture with T 
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Table  A: ANOVA table for the statistical two-way ANOVA analysis performed on the fold changes of the genes of 













F (7, 22) = 3,363 
P=0,0136  
(*) 
F (7, 26) =957,5 
p<0,0001 
(****) 
F (7, 22) =533,6 
p<0,0001 
(****) 
F (7, 24)=169,1 
p<0,0001 
(****) 
F (7, 22) = 20,11 
p<0,0001  
(****) 
Time  F (7, 22) = 3,363 
p<0,0136 
 (*) 
F (7, 26) =957,5 
p<0,0001 
(****) 
F (7, 22) =534,1 
p<0,0001 
(****) 
F (7, 24)=169,2 
p<0,0001 
(****) 
F (7, 22) = 20,10 
p<0,0001  
(****) 
Stimulation F (1, 22) = 8,045 
p<0,0096 
 (**) 
F (1, 26) 
=1550p<0,0001 
(****) 
F (1, 22) = 2553 
p<0,0001 
(****) 
F (1, 24)=1021 
p<0,0001 
(****) 






Fig. A Ct-values for (A) TBP and (B) LTβR for both stimulated and non-stimulated HUV-EC-C cells (stimulated with 
8ng/mL TNFα  and IL-1β) 
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Table  B: Adjusted p-values from the post-hoc analyses of the two-way ANOVA performed on T cell proliferation. T cells 
isolated from healthy blood donors and cocultured with MSCs. 









S VS N 0,4789 0,9923 0,8207 0,9964 0,2623 <0,0001 
S VS T 0,3323 0,9404 0,5555 0,0335 0,0004 <0,0001 





S 0,6147 0,4369 0,0354 0,1087 0,001 0,0001 
N 0,9977 0,367 0,1345 0,0916 0,07 0,0113 
T 0,9547 0,6601 0,3008 0,9196 0,9814 0,4802 
Abbrevations: T: T cells cultured alone; S: T cells in coculture with stimulated MSCs; N: T cells in coculture with non-
stimulated MSCs. 
 
Table  C: Adjusted p-values from the post-hoc analyses of the two-way ANOVA performed on T cell proliferation. T cells 
isolated from SLE patients and cocultured with MSCs. 









S VS N 0,997 0,9737 0,5747 0,9374 0,9055 0,0003 
S VS T >0,9999 0,9859 0,4411 0,0897 0,0064 <0,0001 





S 0,8748 0,4282 0,0205 0,0582 0,0035 0,0001 
N 0,8323 0,3059 0,1928 0,1267 0,0115 0,0087 
T 0,8739 0,5315 0,2851 0,9986 0,9999 0,9572 
Abbrevations: T: T cells cultured alone; S: T cells in coculture with stimulated MSCs; N: T cells in coculture with non-
stimulated MSCs. 
 
Table  D: Adjusted p-values from the post-hoc analyses of the two-way ANOVA performed on T cell proliferation. T cells 
isolated from LN patients and cocultured with MSCs.  









S VS N 0,6862 0,9838 0,9983 0,9583 0,9273 0,708 
S VS T 0,7957 0,8643 0,9593 0,1036 0,0013 <0,0001 





S 0,9923 0,4141 0,0993 0,0863 0,0052 0,0003 
N 0,5915 0,3182 0,0882 0,1533 0,0143 0,0031 
T 0,7182 0,1738 0,1726 0,9993 0,9339 0,9952 




Table  E: Adjusted p-values from the post-hoc analyses of the two-way ANOVA performed on T cell proliferation. T cells 
isolated from healthy blood donors and cocultured with HUV-EC-C. 









S VS N 0,6862 0,9838 0,9983 0,9583 0,9273 0,708 
S VS T 0,7957 0,8643 0,9593 0,0192 <0,0001 <0,0001 





S 0,9923 0,4141 0,00014 0,0412 <0,0001 <0,0001 
N 0,5915 0,3182 0,0011 0,1533 0,0003 <0,0001 
T 0,7182 0,1738 0,0097 0,9993 0,9339 0,9952 
Abbrevations: T: T cells cultured alone; S: T cells in coculture with stimulated HUV-EC-C cells; N: T cells in coculture 






Fig. B: Comparison of the Th subsets when the T cells are cocultured with MSCs in direct contact or in Transwell 
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